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ABSTRACT

TUMOR SUPPRESSIVE ROLE OF UREA CYCLE ENZYMES IN RENAL CARCINOMA
Sanika Vinayak Khare
M. Celeste Simon

Kidney cancer is a common adult malignancy in the United States. Clear cell
renal cell carcinoma (ccRCC), the predominant subtype of kidney cancer, is
characterized by widespread metabolic changes. Urea metabolism is one such altered
pathway in ccRCC. This is reflected in the lowered mRNA and protein levels of enzymes
ASS1, ASL, and ARG2 in tumor samples when compared to the normal kidney. These
three enzymes play a critical role in nitrogen metabolism, and alterations in their levels
and functions have profound effects on cellular growth. ARG2 is located in the
mitochondria of renal cells, and its loss promotes growth by conserving pools of an
essential biosynthetic co-factor, pyridoxal -5- phosphate, and preventing a toxic build-up
of polyamines. However, ASS1 and ASL are cytosolic in their subcellular location, and
ostensibly act independently of ARG2 to suppress growth in ccRCC by depleting cellular
aspartate pools and altering pyrimidine synthesis. Overall, our results uncover a delicate
metabolic balance in ccRCC cells that is disrupted by the re-expression of urea cycle
enzymes. Taken together, our data seek to establish a metabolic tumor suppressive role
for the urea cycle enzymes in ccRCC.
.
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CHAPTER 1: INTRODUCTION

Introduction to inborn errors of metabolism
Inborn errors of metabolism (IEM) are a diverse, yet not uncommon, group of
disorders that occur due to mutations or deficiencies in a single enzyme of a metabolic
pathway. In the early 1900s A.E. Garrod, a British physician, described four such
inherited disorders of metabolism. Since then this number has grown to over 750 IEMs.
IEMs affect about 1/1000 children and are passed on in an autosomal recessive manner
(with a few exceptions). Although a vast majority of IEMS manifest shortly after birth,
some symptoms develop over an individual’s lifetime, and can make diagnosis
challenging. However, early intervention, and genetic testing for newborns has made
some IEMs more manageable (Kiess et al., 2020).
Metabolic disorders in neonates can be classified in a number of ways.
Commonly, they are divided are into three categories: disorders involving biochemical
pathways, disorders involving energy metabolism, and disorders involving complex
molecules (Saudubray et al., 2018).
The first category of IEMs is vast and affects a variety of pathways. It includes
both acute and progressive accumulation of normal and/or toxic metabolites arising from
a block in the affected metabolic pathway. These can result from mutations in amino
acid catabolism, urea cycle defects, carbohydrate defects and porphyrias. The table
below illustrates some examples.
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Disorder

Gene Affected

Manifestation

Management

Phenylketones in urine,
Phenylalanine
Phenylketonuria

Phenylalanine
neurodevelopmental

hydroxylase

restricted diet
defects
Restrict protein
Hyperornithinemiaintake, supplement
Hyperammonemia-

SLC25A15
Triple H

with arginine,
homocitrullinuria, chronic

(Ornithine
Syndrome

glucose, ammonia
neurocognitive defects,

Transporter)

removal with
chronic liver defects,
sodium benzoate
often progressive.
or phenylacetate.
Elevated branched-chain
Protein restriction,

Branched-chain

amino acids (leucine,

Maple Syrup

a-keto acid

isoleucine, valine) in

Urine Disease

dehydrogenase

blood causing

complex

neurological defects and

increased glucose
to promote
endogenous
protein synthesis.
brain injury

Methyl Malonic

Methylmalonyl-

Acidemia

CoA mutase

Increased methyl malonic

Treatment with

acid in blood and urine-

vitamin B12 (mild

neurological defects,

forms), dual renal

hypotonia, renal defects,

and hepatic

pancreatitis.

transplants.

Table 1: Examples of Disorders Involving Biochemical Pathways
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The second category of IEMs involves defects in glucose transport and
metabolism, fatty acid oxidation, and mitochondrial respiration. Whereas disturbances
caused by faulty glucose and fatty acid catabolism can be partially managed by
providing exogenous supplements, mitochondrial defects are usually untreatable with a
dismal prognostic outlook. These include mutations in the electron transport chain,
pyruvate metabolism, tricarboxylic acid cycle, and pentose phosphate pathway.
The final category of metabolic disorders relates to the synthesis, catabolism and
maintenance of complex molecules. These disorders are usually progressive in nature
and do not respond to dietary interventions. They include inborn errors in lysosomal
storage, nucleotide synthesis, cholesterol and bile synthesis, and vesicular trafficking
among others. Diagnosis and management can be difficult and treatment options are
limited (El-Hattab, 2015, Fukao and Nakamura, 2018).
Urea cycle in development and disease
Urea cycle disorders are one of the most common forms of IEMs (Haberle et al.,
2012). They belong to the first category of defects and are caused by malfunctions in
urea cycle components.
Protein homeostasis in the body is a fine balance between protein uptake,
synthesis, and breakdown. Dietary proteins are constantly broken down into amino acids
which are then repurposed for endogenous protein synthesis. This protein breakdown
generates ammonia. The most common enzymatic reactions that result in ammonia
production are listed in the table below.
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Enzyme (location)

Substrate

Glutaminase (brain, skeletal
Glutamine
muscle)
Glutamate Dehydrogenase
Glutamate
(small intestine)
Bacterial Deaminase (large
Amino acids
intestine)
Urease (large intestine)

Urea

Table 2: Sources of Urea in vivo

Ammonia produced by protein catabolism in other tissues is transported to the
liver as glutamine. This glutamine is converted to glutamate to release ammonia, via
transamination. Ammonia is extremely toxic and is converted to the relatively non-toxic
urea by the urea cycle. Although some steps of the cycle are also carried out in the
kidney and other tissues of the body, the liver is the main site of ureagenesis. The nonhepatic urea cycle components are thought to be involved in arginine biosynthesis and
nitric oxide generation.
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Figure 1: The Hepatic Urea Cycle

Figure 1 represents the urea cycle as it is present in the liver. In the first step of
the cycle, the enzyme Carbamoylphosphate synthase 1 (CPS1) catalyzes the
conversion of ammonia and bicarbonate into carbamoyl phosphate. This reaction occurs
in the mitochondrial matrix, and N-acetylglutamate (NAG), magnesium and ATP act as
co-activators. The carbamoyl phosphate thus produced is combined with ornithine to
generate citrulline in a reaction catalyzed by the enzyme ornithine transcarbamylase
(OTC). The transporter SLC25a15 or ORNT1 transports citrulline to the cytoplasm while
citrin (aspartate-glutamate shuttle) carries aspartate from the mitochondria. Enzyme
argininosuccinate synthase 1 (ASS1) condenses citrulline and aspartate to form
argininosuccinate, which is then cleaved by argininosuccinate lyase (ASL) to form
arginine and fumarate. Arginine is finally acted on by arginase 1 (ARG1) to form urea
and regenerate ornithine. The produced urea is subsequently excreted from the body.
5

Urea cycle disorders (UCDs) are caused by mutations or insufficiencies in any of these
components (Erez, 2012, Nagamani, et al., 2011, Erez, et al., 2011). All disorders
barring OTC insufficiency are passed on in an autosomal recessive manner. OTC
insufficiency is X-linked. The table below summarizes the various UCDs (Summar et al.,
2013)
Gene

Frequency

CPS1 (2q25)

1/975,000

Manifestation
Most severe form. Neonatal hyperammonemia
resulting in neurological damage or death.

NAG
Same as CPS1 deficiency but can be completely
Synthase

Unknown
treated with an NAG analog.

(17q21.3)

OTC (Xp21.1)

Most common

Hemizygous male neonates have

- 1/50000 -

hyperammonemia. Late-onset disease is episodic

80000

in nature.
Wide range of symptoms – asymptomatic to

ASS1 (9q34)

1/57000

severe neonatal hyperammonemia and
citrullinemia.
Symptoms are caused by arginine deficiency
and/or argininosuccinate build up. Neonatal

1/70000ASL (7q11.2)

hyperammonemia, cognitive defects,
218000
hepatomegaly/fibrosis, bleeding and coagulation
defects.
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Developmental delay, intellectual defects,
ARG1 (6q23)

1/300,000

hepatomegaly, seizures. Elevated arginine in
blood, urine and cerebrospinal fluid.

SLC25A13/
Increased amino acids in the blood, along with
Citrin

Varied
galactose. Intrahepatic cholestasis.

(7q21.3)
Causes hyperornithinemia, hyperammonemia,
ORNT1

100 cases till

homocitrullinuria. Coagulation defects, vomiting

(13q1)

date

and lethargy are observed. Physical and cognitive
growth is negatively impacted.

Table 3: List of Urea Cycle Disorders

IEM and Cancer
Metabolic rewiring has been long regarded as a hallmark of malignant
transformation. Studying transformed metabolism is not limited to a single event, rather it
is akin to observing changes in a complex and wide network of genes, enzymes,
metabolites and microenvironments. The study of inborn errors of metabolism offers a
unique perspective into understanding cancer metabolism. It allows us to observe
network-wide effects of a single enzyme change – from genetics to protein function to
metabolism. Furthermore, a number of IEMs confer an increased cancer risk (Erez and
DeBerardinis, 2015).
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Tumorigenesis involves excessive growth and cellular transformation, both of
which are accompanied by underlying metabolic changes. There are several
mechanisms by which primary metabolic disruptions in IEMs can cause cancer.
Hepatocellular carcinoma (HCC) is one of the most common forms of cancers
associated with IEMs. Inactivation of certain metabolic enzymes in the liver leads to
chronic and toxic accumulation of intermediates which in turn causes tissue damage,
fibrosis and eventually cancer. IEMs associated with this mechanism include tyrosinemia
type I, hemochromatosis, Wilson’s disease, and mitochondrial DNA depletion
syndromes. In a similar manner, renal cell carcinoma (RCC) is associated with Fabry
disease while bone and hematological malignancies with Gaucher disease (Nelson et
al., 1995, Lithner et al., 1984, Savas et al., 2006, Cassiman et al., 2007).
Similarly, loss of function mutations in metabolic enzymes fumarate hydratase
(FH) and succinate dehydrogenase (SDH, A-D, F) lead to accumulation of their
substrates – fumarate and succinate. These tricarboxylic acid (TCA) cycle intermediates
are implicated in tumorigenesis in some forms of kidney and neuroendocrine tumors.
On the other hand, altered metabolism may give rise to “altered” metabolites.
These “altered” metabolites can promote malignancy without inciting chronic tissue
damage and are often termed “oncometabolites”. The most studied oncometabolite is D2-hydroxyglutarate (D-2HG), produced by a gain-of-function mutations in the TCA cycle
enzymes isocitrate dehydrogenase 1 (IDH1) and IDH2 (Yang et al., 2013, Intlekofer et
al., 2018). Levels of fumarate, succinate and D-2HG affect the activity of a-ketoglutarate
dependent dioxygenases and they in turn modulate the redox balance, hypoxic signaling
and epigenetic landscapes, and lead to malignant transformation. However, children with
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biallelic loss of these enzymes exhibit physical and intellectual growth defects and often
die early because of which they do not get cancers.
Mitochondrial IEMs and Cancer
Mitochondrial disorders form another important link between malignancy and
IEMs. Mitochondria are critical for a number of metabolic processes including the TCA
cycle, oxidative phosphorylation (OXPHOS), biosynthesis of precursors and amino
acids, fatty acid oxidation, and redox balance. Mitochondrial DNA along with nuclear
DNA encodes over 100 components involved in OXPHOS. Mutations in any of these
components can cause IEMs, and suboptimal mitochondrial function can contribute to
tumorigenesis (Carew et al., 2002).
Altered Glucose Flux in IEMs and Cancer
Cancer cells exhibit an interesting metabolic phenotype termed “aerobic
glycolysis” – wherein they underutilize OXPHOS for ATP generation and convert a
majority of their pyruvate to lactate, even in the presence of sufficient oxygen. This is
known as the Warburg effect. It is often accompanied by enhanced flux through the
pentose phosphate pathway (PPP), increased glycolysis and glutaminolysis. Cancer
cells are thought to employ the Warburg effect to generate biomass in form of
nucleotides, proteins and lipids – building blocks for all proliferating cells (Warburg,
1956, Chandel and DeBerardinis, 2020).
Interestingly, a number of IEMs also involve metabolic rewiring wherein the PPP
flux increases along with enhanced glycolysis and glutaminolysis. One such disorder is
glycogen storage disease Ia (GSD Ia) that is caused by a deficiency in glucose-6phosphatase

complex

(G6PC).

G6PC

is
9

the

last

common

step

between

gluconeogenesis and glycolysis. G6PC deficiency causes severe fasting intolerance and
hypoglycemia, and patients require a constant carbohydrate source to offset this. Loss of
G6PC diverts glucose-6-phosphate (G6P) generated by glycogen breakdown towards
glycolysis and PPP, along with increases in lactate production. 75% of GSD Ia patients
develop liver adenomas while 16% develop HCC (Lei et al., 1993).
Urea Cycle Disorders and Cancer
In a similar fashion, urea cycle intermediates are also shunted towards anabolic
routes in cancer. Altered expression of urea cycle enzymes in cancer reduces nitrogen
waste generation while simultaneously redirecting carbon and nitrogen to biomass
generation.
As discussed earlier, the urea cycle is predominantly involved with ammonia
removal in the body. However, there has been evidence of this ammonia being
redirected towards anabolic pathways for amino acid synthesis in breast cancer,
obviating the need for the urea cycle. The amino acids produced from ammonia
incorporation include glutamine and glutamate, which are pivotal in cancer cell growth.
They serve as precursors for biosynthesis of nucleotides, lipids, amino acids,
antioxidants like glutathione, and maintain TCA anaplerosis. Dysregulation of urea cycle
components can contribute towards enhanced glutamine utilization, a hallmark of cancer
cells. (Erez and DeBerardinis, 2015).
Carbamoyl phosphate synthase 1 (CPS1) is the first enzyme of the hepatic urea
cycle (Figure 1). It produces carbomoyl phosphate (CP). CPS1 activity is also contained
in another enzymatic complex called CAD (CPS2, Aspartate transcarbamylase,
dihydroorotase). CAD is present in the cytosol, while CPS1 is located in the
mitochondria. CAD is responsible for pyrimidine synthesis. Recent studies indicate that
10

the differences between mitochondrial and cytosolic pools of CP become blurred in
cancer cells. CP produced by CPS1 is often redirected towards pyrimidine synthesis in
lung cancer cells. Unsurprisingly, CPS1 is often over-expressed in lung and colon
cancers, choliangiocarinomas and some forms of glioblastomas. In these cancers, it is
associated with aggressive disease status and a poor prognosis. On the other hand,
CPS1 is downregulated via promoter methylation in HCC. This downregulation is
accompanied by increased activity of the CAD complex, thereby maintaining enhanced
pyrimidine

synthesis.

The

next

enzyme

of

the

urea

cycle

–

ornithine

transcarbamoyltransferase (OTC) combines ornithine with CP to form citrulline.
However, to aid proliferation, lowering OTC levels would help redirect existing CP pools
towards pyrimidine synthesis. Furthermore, lowered OTC activity will conserve ornithine
for other biosynthetic fates including polyamines, glutamate and proline production.
Thus, OTC expression is downregulated in a number of malignancies (Kim et al., 2017).
Aspartate is a key metabolite in proliferating cells. Cells take it up in miniscule
amounts from the microenvironment and instead depend on de novo synthesis for their
aspartate. Intracellular synthesis of aspartate requires a functional TCA cycle, electron
transport chain (ETC), and healthy mitochondria. Cancer cells often have suboptimal
TCA cycle and ETC function and thus have limited intracellular pools of aspartate. In a
setting of uncontrolled proliferation, the cells would divert aspartate towards pyrimidine
synthesis rather than the urea cycle.
Aspartate is transported from the mitochondria to the cytosol by citrin. Once in
the cytosol, it broadly has two key metabolic fates – conversion to argininosuccinate (by
ASS1) or orotic acid (by the CAD complex). In line with enhanced pyrimidine synthesis,
proliferating cells would upregulate citrin expression and CAD activity, while
11

simultaneously downregulating ASS1 expression. Thus, ASS1 downregulation supports
proliferation by shunting aspartate towards pyrimidine synthesis. This downregulation of
ASS1 comes with another metabolic vulnerability. Cells lacking ASS1 (and ASL), are
arginine auxotrophs and depend on exogenous sources for their arginine supply. As a
result, arginine deprivation has emerged as an attractive therapy in cancers lacking
ASS1 (and ASL) (Rabinovich et al., 2020, Rabinovich et al., 2016, Keshet et al., 2018, Li
et al., 2019, Keshet et al., 2020, Nagamani and Erez, 2016, Keshet and Erez, 2018).
Interestingly, tumors lacking ASS1 exhibit an imbalance in their pyrimidine/purine
ratio, which in turn leads to a novel surface protein signature. Recent studies indicate
that such tumors are exquisitely sensitive to immune checkpoint therapy. Regulation of
ASS1 expression is complex, and diverse factors including MYC, p53, HIF1-a are
reportedly involved (Lee et al., 2018). However, ASS1 is over-expressed in a few
malignancies. High ASS1 levels in colon cancer are thought to support arginine
synthesis and help the cells survive low-nutrient environments.
Role of ASL expression in carcinogenesis is more ambivalent. High ASL
expression is considered a poor prognostic factor in breast, liver and colorectal cancers.
Downregulation of ASL activity is associated with lowered arginine and nitric oxide
synthesis, which can regulate the immune microenvironment and bolster tumor growth in
a context depend manner.
Introduction to clear cell renal cell carcinoma (ccRCC)
Cancers of the kidney are in the top ten adult malignancies in the United States.
In 2020, it is estimated that 65,815 new cases of kidney cancer will be diagnosed, and it
would result in 14,000 deaths. Patients with local disease are offered surgery along with
standard of care chemotherapy and have a 5-year survival rate of 95%. However, if the
12

disease has metastasized, the survival rate drops to 12%. Renal Cell Carcinoma (RCC)
is a genetically heterogenous disease with over 17 genes and pathways implicated in
tumorigenesis. The following table enlists the types of RCC, and their incidence (Linehan
and Ricketts, 2019)
Subtype

Incidence

Clear Cell RCC

65-70%

Papillary RCC

15-20%

Chromophobe RCC

5-7%

Table 4: Renal Cell Carcinoma Subtypes

We will focus on the most common subtype – clear cell renal cell carcinoma (ccRCC).
Genetic and epigenetic landscape of ccRCC tumors
ccRCC tumors are thus named because of their histological appearance.
Grossly, they appear yellowish with necrosis and hemorrhage. Histologically, they
consist of thin walled cells filled with abundant lipids and glycogen – giving the “clear
cell” appearance. More than 90% of ccRCC tumors exhibit loss of chromosome 3p. A
copy of the von Hippel Lindau (VHL) gene is located on chromosome 3p, and is
ubiquitously lost in ccRCC, while the other is mutated or silenced. Other 3p genes that
are commonly lost in ccRCC tumors are PBRM1 (38%), SETD2 (13.2%), and BAP1
(11%). It is interesting to note that common tumor suppressive genes like TP53 and Rb
are mutated in only 11% and <1% of ccRCC tumors, respectively (Mehdi et al., 2017,
Sato et al., 2013).
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VHL is a tumor suppressor gene. It encodes for protein pVHL. pVHL is a versatile
protein that is involved in regulation of glucose metabolism, angiogenesis, cellular
senescence, apoptosis, WNT signaling, NFkB activity, and suppression of epithelial to
mesenchymal transition among other activities. It carries out all of its functions by
recruiting a variety of co-factors and effector proteins. However, the principal function of
pVHL is its role in degradation of hypoxia inducible factors (HIFs). pVHL along with
Elongin B, Elongin C, Cul2, and Rbx1 forms an E3 ubiquitin ligase that marks
hydroxylated HIF subunits for proteasomal degradation under normoxic conditions.
Hypoxia inducible factors (HIFs) have five variants – HIF1a, HIF2a, HIF3a,
HIF1b (or aryl hydrocarbon nuclear translocators 1, ARNT1), and HIF2b. HIF1a and
HIF2a individually form a complex with ARNT1 which translocates to the nucleus and
initiates a massive transcriptional program. Under normal concentration of oxygen, a set
of proteins called prolyl hyrdorxylase (PHD), add an -OH group to HIFa subunits. This
reaction consumes oxygen and thus acts as an oxygen sensor. The hydroxylated HIFa
subunits are then recognized by and marked for degradation by the pVHL led complex.
Under hypoxia, PHDs do not hydroxylate HIFa subunits. Thus, HIFa is not
degraded and accumulates in cells, forms a complex with ARNT1, and translocates to
the nucleus. Loci of the genome where the HIFa-ARNT1 complex bids are called
hypoxia responsive elements (HREs). There are hundreds of HREs spread across the
genome and HIF binding activates a broad transcriptional program in response to low
levels of oxygen. This includes angiogenic, mitogenic, erythropoietic genes and genes
that regulate glucose uptake and metabolism. The same outcome is achieved by VHL
loss – the HIF transcriptional program is activated even in the presence of oxygen.
14

ccRCC tumorigenesis is centered around the VHL-HIF axis and each event
represents a distinct step towards malignant transformation. The initiating event is the
loss of pVHL through mutations and/or epigenetic silencing. This is followed by HIFa
stabilization and constitutive activation. HIFa activation enhances the transcription of
genes involved in angiogenesis (like VEGFA), glucose uptake (GLUT1), survival
(survivin), migration and invasion (CXCR4), and proliferation (EGFR). Thus, HIFa drives
the tumorigenesis in ccRCC. Of note, only HIF2a has been clearly implicated in ccRCC
tumorigenesis, the role of HIF1a is ambivalent. Some studies suggest that HIF1a is in
fact a tumor suppressor and is silenced in ccRCC, while HIF2a is oncogenic. As a result,
HIF2a has emerged as an attractive therapeutic target in ccRCC (Keith et al., 2012).
VHL loss alone is not sufficient to drive ccRCC tumorigenesis. Concurrent
mutations and/or loss in other genes are necessary to achieve that. Fortuitously, in
ccRCC, chromosome 3p loss deletes three more genes and spurs on tumorigenesis.
The aforementioned genes are PBRM1, BAP1, and SETD2. Incidentally, all three genes
are implicated in epigenetic regulation and chromatic modification. Furthermore, they
have been associated with a number of malignancies including melanoma,
mesothelioma, pancreatic cancer, colorectal cancer, and leukemia.
PBRM1 gene encodes for the protein BAF180 which is a part of the chromatin
remodeling SWI/SNF (switching defective/sucrose nonfermenting) complex. More
granularly, BAF180 is the chromatin targeting subunit of the polybromo BRG1associated factor (PBAF) which in turn is one arm of the SWI/SNF machinery. BAF180
can bind to acetylated lysines in histone tails through its six tandem bromodomains. The
recruitment of the SWI/SNF complex to chromatin regulates expression of genes
involved in DNA replication, transcription, cell death, metabolism and proliferation. In
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fact, it a key regulator of a large number of transcription factors. Notably, BAF180 is
known to associate with E-cadherin, thereby modulating cell-cell adhesion and
movement. Through its interaction with chromatin, BAF180 also confers protection from
genome instability and aneuploidy.
Loss or inactivation of PBRM1 results in increased cell growth and migration.
Conversely, re-expression of PBRM1 in RCC cells causes p21 mediated G1 cell cycle
growth arrest. Interestingly, re-expression of mutant BAF180 is unable to suppress cell
proliferation. Furthermore, BAF180 loss in pVHL deficient cells reinforces the HIF
transcriptional signature. As a result of its critical role in ccRCC tumorigenesis, some
groups have used PBRM1 loss to model ccRCC disease progression in mouse models
along with pVHL loss.
BRCA1 Associated Protein -1 (BAP1) is the protein encoded by the BAP1 gene,
which is located between VHL and PBRM1 on chromosome 3p. BAP1 mutations are
observed in uveal melanoma and mesothelioma. Germline BAP1 mutations predispose
to ccRCC, thus implicating the gene in ccRCC initiation akin to VHL. BAP1 protein is a
deubiquitylating enzyme of the ubiquitin C-terminal family and it localizes to the nucleus.
Once in the nucleus, BAP1 forms a complex with breast cancer type 1 susceptibility
protein (BRCA1) and BRCA1-associated RING domain protein 1 (BARD1) and is
involved in critical functions of DNA repair and cell cycle regulation. BAP1 regulates the
G1/S transition and its loss aids uncontrolled proliferation. The exact role of BAP1 loss in
ccRCC is as yet unclear. However, BAP1 loss is associated with activation of a number
of growth pathways like the epidermal growth factor (EGF), nerve growth factor (NGF),
insulin, PI3K, and mTORC1 pathways.
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SETD2 is the fourth gene residing on chromosome 3p that is frequently lost in
ccRCC tumors. It encodes a H3K36 histone methyltransferase. Chromatin wide
reduction in the H3K36me3 histone mark is associated with SETD2 loss. H3K36me3 is
critical for activation of ATM and TP53 mediated DNA damage responses and SETD2
loss interferes with these responses. Thus, SETD2 loss causes aberrations in the repair
of DNA double-strand breaks, mismatch repair and ultimately leads to genomic
instability. Interestingly, the H3K36me3 mark is also associated with heterochromatin
and SETD2 loss is thought to alter chromatin accessibility and affect RNA splicing in
ccRCC tumors.
Lysine Demethylase 5C (KDM5C) is a gene present on the X chromosome and is
mutated in 7-9% of ccRCC tumors. H3K4me3 marks are linked to actively transcribed
chromatin. KDM5C demethylates these marks and interferes with the transcription of
certain genes. Interestingly, HIF turns on KDM5C expression, and KDM5C in turn
represses the expression of a number of other HIF targets. Thus, in the context of
constitutive HIF activity, KDM5C might act as a modulator and regulate HIF target gene
expression in a tumor suppressive manner. KDM5C knockdown in VHL deficient cells
accelerates ccRCC tumorigenesis. Furthermore, KDM5C is broadly involved in
maintaining heterochromatic sites and stability of the genome, and its deficiency tips
cells towards malignant transformation.
Another demethylase, lysine demethylase 6A (KDM6A), is also located on
chromosome X and is mutated in 1% of ccRCC tumors. KDM6A interacts with the
polycomb complex and together are involved in the repression of certain genes.
Mutations in KDM6A alter expression of these repressed genes and promote
proliferation. However, the exact mechanisms for this remain unknown.
17

Both KDM5C and KDM6A escape X-inactivation and belong to a group of genes
called EXITS (Escape from X-inactivation Tumor Suppressors). Their homologs are
present on the Y chromosome and are also downregulated in 40% of the male ccRCC
patients due to Y chromosome deletion. Frequent mutations and deletions in these
genes allude to a significant role in ccRCC growth (Hakimi and Voss, 2018, Ricketts et
al., 2018).
Metabolic landscape of ccRCC
ccRCC is often referred to as a metabolic disorder, owing to its widespread
metabolic rewiring. A vast majority of these changes have been attributed to VHL loss
and HIF stabilization, with HIFs being the driving force behind the altered metabolic
landscape. In this section I will briefly summarize the altered metabolic pathways in
ccRCC tumors (Wettersten et al., 2017, Hakimi et al., 2016, Clark et al., 2019, Yong et
al., 2020, Courtney et al., 2018, Li et al., 2014).
Glucose is an important fuel for a variety of cells types. Under normoxia, nontransformed cells convert glucose to pyruvate which in turn enters the TCA cycle and
ETC to produce ATP. In the absence of oxygen, cells switch to anaerobic glycolysis
converting pyruvate to lactate in a reaction catalyzed by lactate dehydrogenase (LDH).
However, cancer cells – especially ccRCC cells, rely on lactic acid fermentation
irrespective of the oxygen levels. This has been attributed to HIFs driving increased LDH
expression. Recent tracing experiments in ccRCC patients have demonstrated the
complete dependence of ccRCC cells on aerobic glycolysis, thus being completely
Warburg-ian, unlike other malignancies. ccRCC tumors also exhibit increased levels of
the glucose transporter 1 (GLUT-1) along with a number of glycolytic enzymes including
phosphoglycerate kinase, hexokinase, pyruvate kinase, pointing towards enhanced
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glycolysis. This uptick in glycolysis is accompanied by the downregulation of
gluconeogenesis as evidenced by the loss of enzyme fructose bis phosphatase 1
(FBP1). FBP1 expression promotes gluconeogenesis in the cytosol, whereas nuclear
FBP1 prevents HIF-DNA binding, hindering HIF target transcription. Thus, FBP1 loss in
ccRCC tumors has a two-fold advantage – dampening gluconeogenesis and permitting
HIF mediated transcription. Increased GLUT-1 expression might aid immune
suppression in ccRCC, as tumor cells consume more glucose, effectively starving
infiltrating CD8 T-cells.
The TCA cycle is selectively altered in ccRCC tumors – it is downregulated
between succinate and malate and upregulated between citrate and a-ketoglutarate
when compared to the normal kidney. Additionally, reductive carboxylation is
upregulated in ccRCC tumors presumably to aid increases in fatty acid synthesis.
ccRCC tumors increase their glutamine uptake to fuel this enhanced fatty acid synthesis.
HIF2a expression has been shown to be sufficient to drive this glutamine addiction and
TCA cycle alteration.
In addition to fueling fatty acid synthesis, increased glutamine uptake also
contributes to the glutathione pathway. ccRCC tumors have increased levels of reactive
oxygen species (ROS), and increased glutathione production serves as an internal ROS
scavenger. Studies suggest that glutamine withdrawal has detrimental effects on ccRCC
growth.
Altered lipid metabolism is a hallmark of ccRCC tumors. Increased glutamine
uptake and enhanced reductive carboxylation together drive flux towards fatty acid
synthesis. As a result of this, ccRCC cells have increased levels of cholesterol esters
when compared to the normal kidney. In line with this finding, ccRCC tumors have
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enhanced levels of lipid synthesis enzymes – stearoyl-CoA desaturase 1 (SCD1) and
fatty acid synthase (FAS). It is postulated that these lipids are stored to aid membrane
synthesis. Additionally, ccRCC patients have increased levels of acyl carnitines and
carnitines. Although their effect on ccRCC progression is unclear, they can serve as
biomarkers for diagnosis.
Tryptophan metabolism is another altered pathway in ccRCC tumors. Tryptophan
is an essential amino acid. It is involved in three critical metabolic pathways – the
indoleacetate pathway, the serotonin pathway, and the kynurenine pathway. In ccRCC
tumors, the indoleacetate and serotonin pathways are downregulated in favor of the
upregulated kynurenine pathway. Combining kynurenine pathway blockade with anti-PD1 therapy is currently under clinical trials.
Pentose pathway serves as a shunt to glycolysis that diverts glucose-6phosphate towards ribose sugar synthesis. Glucose-6-phosphate dehydrogenase is the
rate-limiting enzyme in this pathway and enhanced G6PD levels has been reported to be
protective in kidney disease. ccRCC tumors have increased flux through PPP perhaps
for its tissue specific protective advantages. Additionally, G6PD activity also promotes
cellular proliferation.
Animal models in ccRCC
Development of a genetically engineered mouse model (GEMM) for ccRCC has
been an ongoing challenge for researchers. Loss of VHL, the driver event in ccRCC,
does not result in tumorigenesis in mice, thus highlighting the need for a “second-hit”.
SETD2, PBRM2, and BAP1 are the other top three altered genes in ccRCC. They all
reside on chromosome 3p along with VHL – thus modeling loss of 3p would serve as a
good strategy for ccRCC. However, in mice Vhl is on chromosome 6, Setd2 on
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chromosome 9, and Pbrm1 and Bap1 on chromosome 14 – making modeling
substantially more complex. Thus, modeling human ccRCC progression in mice has not
been very fruitful (Wolf et al., 2020).
Nargund et al. employed the Ksp-Cre system to conditionally delete Vhl and
Pbrm1 in the renal epithelium (Nargund et al., 2017). In this model the mice developed
polycystic kidney disease (PKD) by 6 months of age and 50% of them developed tumors
by 10 months. The tumors resemble human ccRCC tumors with the clear cytoplasm, HIF
activation and mTOR involvement. On the other hand, Gu et al. developed a Vhl and
Pbrm1 conditional knockout model with paired box gene 8 (Pax8) as the driver Cre. 85%
of the mice developed tumors by 9 months of age and the tumors resembled human
ccRCC tumors with PBRM1 loss.
BAP1 is mutated in 10-15% of ccRCC cases and combining BAP1 loss with VHL
loss has been tried out for ccRCC model development. Simultaneous deletion of Bap1
and Vhl with Six2 (a nephron progenitor transcription regulator) as a Cre driver led to
ccRCC development, but the pups died within a month. Utilizing Pax8 as the driver Cre
to delete Vhl and heterozygously alter Bap1 resulted in ccRCC-like tumors with the
“clear cell” histology (Gu et al., 2017).
A common alteration in ccRCC tumors is MYC activation. Combining Vhl loss
with doxycycline induced c-MYC activation along with deletion of a tumor suppressor
gene CDKN2A (INK4A/ARF), Bailey et al. generated three different mouse models. CMYC activation alone produced papillary RCC (pRCC) like tumors, while c-MYC
activation plus Vhl loss resulted in tumors with ccRCC features. Finally, the combination
of c-MYC activation, Vhl loss, and Cdkn2a deletion resulted in an aggressive ccRCC
phenotype with liver metastasis in 30% of the mice. Although an excellent model to
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study aggressive disease, only 6% of ccRCC patients report alterations in these genes
(Bailey et al., 2017).
Employing single nucleotide mutations in other common tumor suppressor
genes, Rb and Tp53, along with Vhl loss, Harlander et al. developed a ccRCC model.
More than 80% of these triple-mutant mice developed tumors in 25-61 weeks, with each
mouse averaging 5 tumors, and males getting more tumors than females (Harlander et
al., 2017).
SETD2 mutant models have not been developed yet. Similarly, comprehensive
analysis of the tumor microenvironment, and drug responses has not been carried out in
these GEMMs. Furthermore, these models use Cre drivers to delete genes during
embryonic development. There is an unmet need to develop models that can trigger
sequential deletions in adult mice to better model the natural progression of human
ccRCC.
As a work around for complex GEMM development, the field has utilized
xenograft models of ccRCC. These involve injecting ccRCC cells orthotopically in the
renal capsule or subcutaneously in immunocompromised mice. Xenograft and patient
derived (PDX) models have been shown to maintain histology, gene expression, copy
number variations, and mutagenic profiles as patient tumors. However, they fall short in
studies relating to immune responses, tumor microenvironment and extra-cellular matrix
modeling. Nonetheless, they serve as a great tool to assess genetic alterations, and
drug responses in ccRCC.
Therapeutic landscape of ccRCC
ccRCC treatment depends on the stage of the disease at diagnosis. For early
stage I/II ccRCC localized to one kidney, surgery has been the most effective option.
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This generally involves either radical or partial nephrectomy contingent on the extent of
the spread. Surgery is not followed by adjuvant chemotherapy. As mentioned earlier,
patients with localized disease have high 5-year survival rates. The same is not true for
metastatic disease. Surgery is also not a viable option after the disease has spread.
Furthermore, ccRCC tumors are resistant to radiation and traditional chemotherapy with
response rates being between 0-10%. Typically, ccRCC tumors were treated with
cytokines, while other forms of chemotherapy resulted in dismal responses coupled with
severe adverse events (Huang and Hsieh, 2020).
Interleukin-2 (IL-2) is produced by activated CD4+ T cells and leads to
differentiation of T cells to helper T1 and T2 cells. Furthermore, it induces CD8+ T-cell
and natural killer cell cytotoxic activity. Exogenously provided recombinant IL-2 is
thought to boost cytotoxic activity in the tumor microenvironment and help treat the
tumors. IL-2 treatment was approved in 1992 and provided modest benefits over
radiation and traditional chemotherapy. However, only 7-10% of the patients have
complete and durable responses for up to 20 years after the initial treatment. A majority
of the patients are partial responders and often relapse. Over 85% of the patients have
adverse side effects including but not limited to anemia, respiratory distress, and
arrhythmias.
Interferon Alpha (IFN-a), a cytokine, enhances natural killer cell activity along
with macrophage and dendritic cell responses and helps boost antitumor immunity.
However, only 6-15% of patients achieved partial responses, while less than 5% had
complete remission. Broadly, IFN-a

was better tolerated than IL-2 and is being

investigated further in combination trials.
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Before 2004, cytokine treatment, albeit ineffective, was the mainstay of ccRCC
treatment. The poor responses and high toxicities led researchers to explore other
therapeutic avenues. VHL drives ccRCC tumorigenesis and also leads to activation of
vascular endothelial growth factor (VEGF) – a proangiogenic factor. Interestingly, ccRCC
tumors are densely vascular thus, making them an excellent target for anti-VEGF
treatment. A plethora of VEGF inhibitors have been approved for ccRCC treatment. In
addition to their anti-angiogenic properties, these drugs also target other growth factors
such as the platelet-derived growth factor receptor. Anti-VEGF treatment leads to
normalization of the tumor vasculature and promotes antitumor immunity by enhancing
tumor accessibility.
Sorafenib was the first targeted treatment approved for ccRCC. However, it only
marginally improved long-term outcomes when compared to IFN-a treatment as a firstline therapy. It fared better in a second-line setting, significantly increasing progression
free survival. Sunitinib, another monoclonal antibody therapy, showed partial responses
in 34% of patients and was significantly less toxic than cytokine therapy. Additionally, it
improved progression free survival (PFS) from 5 months (IFN-a) to 11 months. Thus,
sunitinib was recommended for first-line treatment in ccRCC.
Bevacizumab, an VEGF inhibitor, when combined with IFN-a showed remarkable
results (10.2 vs 5.4 months PFS) when compared to IFN-a alone. However, the patients
also experienced higher incidences of adverse events. Another inhibitor, pazopanib
improved survival in treatment naïve patients (11.1 months vs 2.8 months) with median
response duration of 1 year. It also had significantly lower adverse events and better
quality of life compared to sunitinib. Pazopanib is preferred over sunitinib for first-line
therapy. More recently, axitinib has been approved as a second-line therapy after
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sunitinib or sorafenib and has showed improved survival. Current trials involve axitinib
dose escalation in treatment naïve patients and combination therapies.
Another dysregulated pathway is mTORC1 signaling, making it an attractive
target for treatment. Rapa-logs like temsirolimus and everolimus are used to target
mTORC1 and inhibit its formation. Temsirolimus modestly improved survival over IFN-a
but had a poor toxicity profile. It failed to improve survival in a second-line setting.
Everolimus, on the other hand, excelled in the second line setting after failure with
sunitinib or sorafenib, almost doubling PFS and being well-tolerated.
About 1/3rd of RCC tumors express programmed death-ligand 1 (PD-L1), while
over 50% of the tumor infiltrating immune cells express PD-1. Thus, RCC tumors are a
suitable candidate for immune checkpoint inhibitors. There are two main categories –
anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and PD-1/PD-L1 inhibitors.
CTLA-4 inhibits T-cell activation and blocking CTLA-4 enhances antitumor immunity.
Similarly, PD-1/PD-L1 cascade downregulates T-cell activation, and its inhibition
reduces immunosuppression in tumors.
PD-1 inhibitor, nivolumab, improved overall survival from 19.6 months
(everolimus) to 25 months in patients that had failed first line treatment with an
antiangiogenic agent. Patients receiving nivolumab also experienced fewer side effects.
Combining nivolumab with ipilimumab (CTLA-4 inhibitor) resulted in increased overall
survival when compared to sunitinib. Furthermore, poor to median risk patients receiving
the combination therapy experienced fewer adverse effects, had a better quality of life,
and had a higher rate of complete responses that sunitinib alone.
Tyrosine kinase receptor inhibitors (TKIs) are another class of drugs approved for
RCC treatment. Cabozantinib, a MET and AXL receptor tyrosine kinase inhibitor that
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also blocks VEGF activity, was approved for second-line therapy in RCC. It improved
survival over everolimus alone, but had similar toxicity. Another TKI targeting VEGF,
Lenvatinib when combined with everolimus almost triples the PFS (14.6 months vs 5.5
months) when compared to everolimus alone. However, the combination is extremely
toxic and hence the risk/benefit ratio needs to be carefully assessed.
Combination therapy has been proving to be effective in RCC. In 2019, axitinib
along with pemnrolizumab (anti PD-1 antibody) got approved for therapy. This
combination improved 12-month survival in 90% of the patients when compared to 78%
in sunitinib treated patients. However, there was an increase in adverse events as well.
Similarly, combining axitinib with avelumab (anti PD-L1 antibody) resulted in higher PFS
when compared to sunitinib with comparable toxicities. In both these studies, PD-1 or
PD-L1 expression in the tumor did not affect the final outcome.
Treatment for ccRCC has gone through a sea of change in the past two decades.
Enhancing effectivity while controlling adverse effects and maintaining a good quality of
life have been the tenets of drug discovery for ccRCC. Despite the progress made, there
is an unmet need to develop novel treatment options that can be effective in a majority of
the patients and provide long lasting remissions. Knowledge of ccRCC metabolism can
aid drug discovery and alter the therapeutic landscape.
Main Hypothesis and Objectives
The objective of my thesis work has been to elucidate the role of urea cycle
enzymes in clear cell renal cell carcinoma (ccRCC) progression. Since these enzymes
are almost universally under-expressed in ccRCC, the main aim of this endeavor was to
investigate the pro-proliferative benefit provided by urea cycle downregulation. To
address this question, I broke down the study into two spatially distinct sets of enzymes
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– the mitochondrial arginase 2 (ARG2) and the cytosolic argininosuccinate synthase 1
(ASS1), and argininosuccinate lyase (ASL). I employed a variety of in vitro and in vivo
proliferation assays to ascertain the effect of enzyme loss in normal renal cells, and
enzyme re-expression in ccRCC cells. Loss of urea cycle enzymes promotes growth in
normal kidney cells, while their re-expression suppresses growth in ccRCC cells.
Furthermore, I used mass spectrometry based steady-state and labeled substrate
measurements of metabolites to expand on the mechanistic underpinnings of this
suppression. Finally, based on the metabolic landscape of ccRCC tumors, I attempted to
rescue the growth suppression induced by enzyme re-expression either with a co-factor
(PLP, ARG2) or with nucleosides (cytidine and thymidine, ASS1+ASL).
In Chapters 2 and 3, I explore these questions further, while in chapter 4 I
summarize the work and discuss unanswered questions from this project.
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Chapters 2 and 3 have been adapted from the following articles:
Ochocki, J. D., Khare, S., Hess, M., Ackerman, D., Qiu, B., Daisak, J. I., ... & Li, B.
(2018). Arginase 2 suppresses renal carcinoma progression via biosynthetic cofactor
pyridoxal phosphate depletion and increased polyamine toxicity. Cell metabolism, 27(6),
1263-1280.

and

Khare S., Lobel G., Kim L., Lee P., Keith B., Simon MC. (in preparation).
Argininosuccinate synthase 1 and argininosuccinate lyase suppress growth in clear cell
renal cell carcinoma by depleting cellular aspartate and altering pyrimidine synthesis.
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CHAPTER 2: METHODS AND MATERIALS
Experimental Model and Subject Details
Mice
Xenograft tumor experiments were approved by the Animal Care and Use
Committee at the University of Pennsylvania. Female NIH-III nude mice (Charles River,
6-8 weeks) were injected subcutaneously into each flank with 5 million ccRCC cells in a
1:1 mixture of PBS and Matrigel (Corning 356234) with an injection volume of 200 μL.
Once palpable tumors were established, tumor volume was monitored by caliper
measurements. For doxycycline induced expression of enzymes, xenograft injections
were performed as above, and tumors were allowed to grow till 200mm3 before switching
the diet to a dox containing chow (200mg/kg). Upon completion of the experiment, the
animals were sacrificed by CO2 inhalation and xenograft tumors were dissected for
downstream analyses.
Cell lines and Cell Culture Conditions
Authenticated (short tandem repeat profiling) human cell lines HK-2, 786-O, 769P, A498, RCC4, RCC10, UOK101, and UMRC2 were obtained from the American Type
Culture Collection. RCC10 was a kind gift from W. G. Kaelin (Dana Farber Cancer
Institute, Boston, MA). Cells were cultured for a maximum of 4 weeks before thawing
fresh, early passage cells. All cells are routinely confirmed to be Mycoplasma negative
(MycoAlert; tested every 3 months). ccRCC cells were cultured in DMEM containing
10% FBS and Pen/Strep while HK-2 proximal tubular epithelial cells were cultured in
Keratinocyte-SFM medium supplemented with human recombinant epidermal growth
factor and bovine pituitary extract. To mimic tumor microenvironmental O2 levels, 786-O
cells were grown under hypoxia. Hypoxic conditions (0.5% O2) were achieved in a
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Ruskinn in vivo2 400 workstation, by supplementing ambient air with balanced N2 and
CO2. HK-2 cells don’t survive 0.5%-1% O2 beyond 48 hours; therefore, 1% FBS and 1
mM glucose culture conditions were employed to mimic microenvironmental stress
typical of renal tumors. For arginine labeling assays, cells were maintained in argininefree DMEM supplemented with 10% dialyzed FBS and 398.1 μM 15N4-arginine (standard
DMEM arginine concentration). Similarly, for labelled glucose and glutamine studies,
cells were cultured with the labelled substrate for 24 hours (10mM U-13C6- D- glucose,
low serum, 4mM glutamine) and 3 hours (4mM
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N2 L-glutamine, low serum, 1mM

glucose). For low-glucose conditions, cells were incubated in glucose-free DMEM
supplemented with 1 mM glucose.
Constructs and Viral Transduction
Lentivirus was produced by transfecting HEK-293T cells with the indicated
expression plasmid, pRSV-Rev, pMDL, and pCMV-VSV-G plasmids (4th generation
lentiviral system) using Fugene6 transfection reagent (Promega). The virus was
harvested 48 hours after transfection. For viral transduction, cells were incubated with
medium containing virus 24 hours. Cells were allowed to recover for 24 hours before
antibiotic selection, and surviving pools were utilized for downstream analyses (with the
exception of clonally selected HK-2 cells, detailed below).
The lentiviral vector pLKO.1 Scramble (plasmid no. 17920) was obtained from
Addgene.

pLKO.1

(TRCN0000051018),

lentiviral
ARG2

vector

expressing

SH-2

hairpins

against

(TRCN0000051020),

ARG2
ASS1

SH-1
SH-3

(TRCN0000045554), ASS1 SH-4 (TRCN0000045553), ASL SH-4 (TRCN0000078308),
and ASL SH-5 (TRCN0000078309) were obtained from The RNAi Consortium (TRC) at
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the Broad Institute and GE Dharmacon. For genetic knockout using CRISPR/Cas9, the
lentiviral vector lentiCRISPR v2 was obtained from Addgene (plasmid no. 52961). Guide
RNA’s (sgRNA’s) were cloned into this plasmid and single knockout clones were
screened and selected following previously established methods (Sanjana et al., 2014).
The sgRNA sequences that were positive for the desired knockout were as follows:
ARG2

(caccgGAAGAAATCCGTCCACTCCG

and

the

complementary

strand

aaacCGGAGTGGACGGATTTCTTC), ASS1 (caccgCAGCCACACGAGGATGCACG and
the

complementary

strand

aaacCGTGCATCCTCGTGTGGCTG)

(caccgGAAGGGGCTTTACATGTGCG

and

and

ODC1

complementary

aaacCGCACATGTAAAGCCCCTTCC).
Sequence verified cDNA constructs were obtained from the Mammalian Gene
Collection (GE Dharmacon) and were subcloned into the pCDH-CMV-MCS-EF1Puromycin mammalian expression vector (System Biosciences CD510B-1). Stable cell
line generation with multiple cDNA’s was achieved using either of two additional
mammalian expression vectors with different selectable markers: pCDH-CMV-MCSHygromycin or pCDH-CMV-MCS-Neomycin (System Biosciences). ARG2 cDNA
construct: MHS6278-202800846. ASS1 cDNA construct: MHS1010-202694229. OAZ1
cDNA construct: MHS6278-202858287. ASL cDNA construct: MHS6278-202755499.
The ARG2 (H160F) mutant was generated using Stratagene’s QuikChange II
mutagenesis kit (Agilent). pLJM1-Flag-RagBGTP-Q99L mutant plasmid was obtained from
Addgene (plasmid no. 19315) and subcloned into pCDH-CMV-MCS-Neomycin (System
Biosciences). The cDNA for human excitatory amino acid transporter 1 (hEAAT1) was
obtained from Addgene (plasmid no. 32813) and was subcloned into pCDH-CMV-MCS31

Neomycin. Constitutive mTORC1 constructs were a kind gift from David Sabatini
(Addgene plasmid no. 69015 and 69006). These constructs were subcloned into pCDHCMV-MCS-Puromycin or hygromycin.
Western Blot Analysis
Cells were harvested in lysis buffer (40 mM HEPES pH=7.4, 2 mM EDTA, 10 mM
pyrophosphate, 10 mM glycerophosphate, 1% Triton X-100) containing Roche complete
ultra-protease/phosphatase inhibitor (cat. 05892791001). For western blots of xenograft
tissue, approximately 5-10 mg of tissue was suspended in 500 μL lysis buffer and
homogenized on ice using a Tissue-Tearor (Biospec, 985370). Samples were
centrifuged at 20,000 g for 15 min at 4°C. Protein lysates were resolved by Tris-Glycine
SDS-PAGE and were transferred to nitrocellulose membranes (Biorad #162-0115, 0.45
μm pore size for all experiments, except when probing for 4E-BP1 when 0.2 μm pore
size was used). All membranes were incubated with the indicated primary antibodies
overnight at 4°C and were diluted in TBST (20 mM Tris, 135 mM NaCl, and 0.02%
Tween 20) supplemented with 5% bovine serum albumin. Primary antibodies were
detected with horseradish peroxidase-conjugated secondary antibodies followed by
exposure to ECL reagents, except ARG2, ASS1, and ASL which were incubated with
fluorescently conjugated secondary antibodies and detected on the Li-COR Odyssey
CLx imaging system.
TCGA RNA-seq Analysis
Level 3 RNA-seq data for ccRCC and normal kidney samples were downloaded
and analyzed from the TCGA as previously described (Li et al., 2014). Briefly: differential
gene expression analysis of tumor and normal samples was performed using DeSeq
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(Bioconductor Version 2.12). Normalized counts, P values, false discovery rate, adjusted
P values (p-adj), and fold expression change for each gene were exported. To perform
the gene set analysis, a comprehensive list of 2,752 genes encoding all known human
metabolic enzymes and transporters were clustered into functional sets according to the
metabolic pathways annotated by the Kyoto Encyclopaedia of Genes and Genomes
(KEGG) (http://www.genome.jp/kegg/). The cut-off value of p-adj was set to 0.1 to
exclude genes not consistently detected by RNA-seq. Survival analysis of the data was
performed in GraphPad Prism and statistical effects were analyzed using the log-rank
(Mantel-Cox) test.
Immunohistochemistry
Normal and ccRCC kidney tissue sections (from Cooperative Human Tissue
Network) and tissue microarray slides (KD802, KD804, KD481, KD482, KD244, KD901,
KD601, KD70, KD1503, KD601 from US Biomax) were deparaffinized by baking slides
at 50°C for 20 min. The slides were rehydrated in series of ethanol solutions and
endogenous peroxidase activities were quenched by 1% H2O2 in distilled water for 30
min. After three washes in TT buffer (500 mM NaCl, 10 mM Trizma, and 0.05% Tween20), antigen retrieval was performed by boiling slides for 20 min in a citrate-based
antigen unmasking solution (Vector Labs, H3300). After cooling down to room
temperature, slides were blocked in 2% normal goat serum and 4% BSA in Tris buffer
with Tween 20 and then blocked with avidin and biotin solutions (Vector Labs, SP-2001).
Next, tissue slides were incubated with various primary antibodies at 4°C overnight. After
three washes in TT buffer, biotinylated secondary antibody was added onto these slides
for 1 hour. Sections were then processed using the Vectastain Elite ABC Kit (Vector
Labs, PK-6100) and DAB peroxidase substrate kit (Vector Labs, SK-4100), dehydrated
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in a standard ethanol/xylenes series, and mounted in 75% v/v Permount (Fischer, SP15500) in xylenes.
Immunofluorescence
Immunofluorescence of mTOR in 786-O ccRCC cells was conducted as
previously described (Clippinger and Alwine, 2012). Briefly: cells were plated in 35 mm
dishes in which a 12 mm coverslip was placed on the bottom. After 24 hours, the cells
were washed three times with PBS and fixed for 20 min in 4% paraformaldehyde at
room temperature. Cells were permeabilized in PBS containing 0.5% Triton X-100 and
blocked in PBS containing 5% bovine serum albumin (blocking buffer). Primary
antibodies against mTOR (Santa Cruz, sc1549) and LAMP (BD Biosciences, 555803)
and secondary antibodies (Alexa Fluor 594 and Alexa Fluor 647, Invitrogen) were diluted
in blocking buffer. Coverslips were washed three times in PBS, rinsed in H2O, and
mounted on slides using VectaShield mounting medium containing 4′6′-diamidino-2phenylindole (DAPI) (Vector Laboratories). Slides were examined using a Nikon Eclipse
E600 (40x objective) microscope, and pictures were taken using a Hamamatsu camera.
Quantitative RT-PCR
Total RNA was isolated using the RNA easy purification kit (Qiagen, 74104).
cDNA was synthesized using a High Capacity RNA-to-cDNA kit (Applied Biosystems,
4368814). qRT-PCR was performed on a ViiA7 Real-Time PCR system from Applied
Biosystems. Predesigned Taqman primers were obtained from Life Technologies for the
following

genes:

ACTB

(HS01060665_G1),

18S

(HS03928985_G1),

(HS01597989_G1), ARG2 (HS00982833_M1), and ASL (Hs00902699_M1).
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ASS1

Anchorage-independent growth assay
ccRCC cells stably expressing ARG2, ASS1, ASL, PDXK, or vector control were
plated at a density of 6,000 cells per well (using 6-well plates) in complete DMEM
containing 0.3% agarose (low-melt 2-hydroxyethylagarose, Sigma Aldrich A4018), onto
underlays composed of DMEM containing 0.6% agarose. Additional media was added to
the cultures once per week, and after three weeks of growth the colonies were
quantified. Similar experiments were performed for HK-2 cells and ccRCC cells with
knockdowns.
Liquid-overlay spheroid growth assay
Three-dimensional spheroid cultures were generated using a liquid overlay
technique as previously described (Khaitan et al., 2006). Briefly: Twenty-four–well plates
were coated with 1% agarose in DMEM before plating 100,000 cells per well in DMEM
plus 10% FBS. To promote spheroid formation, plates were swirled before incubation.
Media were changed every 2 days, and spheroids were harvested and measured after 9
days. Measurement of spheroid volume was conducted using ImageJ software by
measuring two orthogonal diameters and calculating the geometric mean radius, given
by r =

d1d2
, where r is the radius and d1 and d2 represent the measured diameters.
2

Spheroid volume was calculated as V =

4 3
π r . To calculate the number of cells per
3

spheroid, 12 spheroids were pooled and dissociated with accutase for 10 min at room
temperature. After centrifugation, the cells were counted with a hemocytometer; the
count was divided by 12 to get the average number of cells per spheroid and this
represented one replicate value.
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Matrigel-based spheroid growth assay
Matrigel- based 3D spheroids were generated using a technique previously
described in (Lewis et al., 2015; Vinci et al., 2012). Briefly: 3000 cells per well were
plated in a 96-well “low adherence” plate along with DMEM plus 10% FBS and 2.5%
matrigel. Plates were centrifuged at 1700 rpm to promote spheroid formation, and then
imaged every two days for two weeks using the EVOS FL Auto Imaging System.
Spheroid volume was calculated using a previously published ImageJ macro (Ivanov et
al., 2014).
Cell Growth Assays
Cell growth assays were performed with either standard counting or using WST-1
reagent. For standard counting: multiple cultures of HK-2 or ccRCC cells were plated in
6 cm dishes at 50,000 cells/plate (ccRCC) or 100,000 cells/plate (HK-2) in complete
DMEM. For growth assays performed in low-glucose and low-serum conditions, cells
were maintained in glucose-free DMEM supplemented with 1% dialyzed FBS and 1 mM
glucose. Each day, one set of culture plates was collected and counted. For WST-1
growth assays: HK-2 or ccRCC cells were plated in 96-well plates at 500 cells/well
(ccRCC) or 1,500 cells/well (HK-2) and allowed to attach overnight (1 - 96-well plate for
each day of the assay). The following day, the media was changed with 200 μL of
complete DMEM supplemented with assorted small molecules (e.g. putrescine, arginine,
ornithine, etc.), depending on the assay (see figures for exact concentrations used in
each experiment). The cells were subjected to WST-1 (Sigma Aldrich, 11644807001)
assay following manufacturers protocols; this was considered Day 0. This was repeated
for each day of the assay and the data in each experiment were normalized to the
starting cell number at Day 0 of the assay.
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For polyamine toxicity studies, we estimated the concentration of putrescine per
cell using our data and published values for cell doubling time and the per cell volume
(National Cancer Institute Developmental Therapeutics Program, NCI-60 Cell line Data:
https://dtp.cancer.gov/discovery_development/nci-60/cell_list.html) and protein content
(Dolfi et al., 2013). With these estimations, we determined that normoxic 786-O vector
control cells contain approximately 3.3 mM putrescine per cell, and that ARG2 reexpression increased this by approximately 25% to 4.5 mM/cell. Hypoxia increases the
uptake of exogenous putrescine, and accordingly we found that hypoxic 786-O vector
control cells contain approximately 6.7 mM putrescine/cell, twice the amount under
normoxia. ARG2 expression raised the levels even further to 8.2 mM/cell in this setting.
It is important to note that these calculations are estimates based on literature values of
cell volume and protein content per cell. Nonetheless, we feel it provides an adequate
estimation of the putrescine content per cell, which justifies treating cells with 1-10 mM
putrescine, spermine, and spermidine.
Arginase Activity Assay
Arginase activity was determined using the Abnova Arginase Activity Assay Kit
(KA1609) following manufacturers protocols. Briefly: 786-O ccRCC cells expressing
empty vector, ARG2 wild type, or ARG2 H160F were lysed in lysis buffer (see western
blot analysis section for recipe), which was used directly in the assay. A urea standard
curve was made, and the samples were mixed with assay buffer and incubated for 1
hour at room temperature, after which the absorbance was read at 430 nm to quantify
the urea produced. Data were normalized to protein concentration in each sample.
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Urea concentration was measured in 786-O xenograft tissues using the BioVision
Urea Colorimetric Assay Kit K375-100 following manufacturers protocols.
Metabolomics Analysis
Mass spectrometry–based metabolomics analysis of primary ccRCC was
performed with Metabolon, as previously described (Li et al., 2014). Additionally,
unbiased metabolomics analysis of 786-O ccRCC xenograft tissue expressing either
empty vector or ARG2 was performed with Metabolon, in the same manner as (Li et al.,
2014).
Arginine, Citrulline, and Aspartate Measurement via LC/MS
786-O ccRCC cells expressing empty vector, ARG2, and/or ASS1 were cultured
for 24 hours, washed, and quenched by the direct addition of 1 mL −80°C 4:1
methanol:water (v/v) to the cell culture dish. Plates were placed at −80°C for 20 min,
scraped, and transferred into Eppendorf tubes. Samples were pulse sonicated on ice for
30 seconds at a rate of 1 pulse/sec prior to centrifugation at 16,000 × g at 4°C for 10
minutes. The supernatants were then transferred to clean glass tubes and evaporated to
dryness under nitrogen. Dried residues were resuspended in 100 μL of mobile phase A
(5 mM ammonium acetate in water) for LC/MS analysis, which was conducted as
previously described (Aird et al., 2015).
15

N-Arginine Metabolite Tracing
Prior to metabolic labeling assays, cells were maintained in SILAC Flex arginine-

free DMEM (A24939-01) supplemented with 10% dialyzed FBS and 398.1 μM arginine
(standard DMEM concentration). This media also lacks glucose, phenol red, glutamine,
and lysine, which were added back to standard DMEM concentrations (25 mM, 15.0
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mg/L, 4.0 mM, and 0.798 mM, respectively). For labeling studies, HK-2 cells were plated
in 10 cm dishes in low glucose (1 mM) and low serum (1%) conditions (SG) and
incubated for 48 hours prior to changing the media to SILAC Flex SG media
supplemented with 398.1 μM 15N4-arginine, which was then incubated for 24 hours. 786O cells were plated in 10 cm dishes in complete SILAC Flex DMEM and placed under
0.5% O2 hypoxic conditions for 48 hours prior to changing the media to SILAC Flex
DMEM supplemented with 398.1 μM

15

N4-Arginine, which was then incubated for an

additional 24 hours in hypoxia. Similarly, cells were cultured in complete DMEM for 24
hours before being switched to 1% FBS and 4mM

15

N2-Glutamine and 1mM Glucose for

3 hours or 10mM U-13C6-Glucose and 4mM glutamine for 24 hours.
The cells were extracted and analyzed as previously described (Nissim et al.,
1999; Nissim et al., 2011). Briefly, cells were washed twice with ice-cold PBS and then
scraped in 4% perchloric acid (PCA) on ice, which was then freeze-thawed for three
cycles. Cell extracts were collected and neutralized using 5 M KOH. The neutralized
PCA extract was used for measurement of
and citrulline. The production of

15

15

N enrichment in arginine, urea, ornithine

N-labeled urea (M+2, containing two

15

N), or proline

from [U-15N] arginine was measured using GC-MS, after separation from neutralized
PCA extract with an AG-50 column and TBDMS derivatization, as in (Nissim et al., 1999;
Nissim et al., 2011). Measurement of labelled products was performed using LC/MS
(Agilent LC 1260 Infinity and Agilent 6410 Triple-Quad MS). Samples prepared from
neutralized PCA extracts and derivatized with ethylchloroformate. For measurement of
15

N enrichment we used the MRM, ion-pair links 275-70 and 279-70 for arginine; 276-70

and 278-70 for citrulline; 233-187 and 235-189 for putrescine; and 305-70 and 307-70
for ornithine.
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Measurement of pyridoxal, pyridoxal phosphate, pyridoxine and pyridoxamine
levels was done using LC/MS, using Poroshell 120EC-C18 column (Agilent). The MRM
used were: 248-150 for pyridoxal phosphate; 168-150 for pyridoxal; 170-152 for
pyridoxine; and 169-152 for pyridoxamine. All preparations and measurements were
performed in the dark due to light sensitivity.
Cell Cycle Analysis
Cells were plated in 10 cm plates until ~60% confluency. To block cells in G1
phase, cells were treated with 20 µM lovastatin (Abcam) for 24 hours and harvested for
analysis. To block cells in early S phase, a double thymidine block was performed by
adding 200 µl of 100 mM thymidine (Sigma-Aldrich) to the media for overnight treatment.
Cells were released from thymidine block by aspirating media, washing the cells and
changing media into media containing 25 µM deoxycytidine (Sigma-Aldrich) for 8 hours.
Media was changed back to thymidine containing media and incubated overnight, before
cells were harvested for analysis. To synchronize cells in G2 phase and mitosis,
following a double thymidine block, cells were first released as before for 2 hours. For
G2-block, RO3306 (Sigma-Aldrich) was added to the cells (10 µM) for 10 hours. For
mitosis block, nocodazole (0.1 µg/ml) (Sigma-Aldrich) was added for 10 hours. Mitotic
cells were then collected by mechanical shake off.
The position of synchronized cells was confirmed by propidium iodide (PI)
staining. Cells were collected in 15 ml conical tubes and centrifuged at 400 xg for 5 min.
Supernatant was discarded, washed with 5 ml PBS, and centrifuged at 400 xg for 5 min.
Supernatant was discarded and cells were re-suspended in 500 µl cold PBS. 100%
ethanol (5 ml) was added drop wise while gently vortexing to fix the cells and kept
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overnight at -20 °C. Cells were spun down at 400 xg for 5 min and supernatant was
discarded. Cells were washed with cold PBS and spun down at 400 xg for 5 min. Cells
were re-suspended in 500 µl PI staining solution (PBS + 50 µg/ml PI (Sigma-Aldrich) +
100 µg/ml RNAse A (QIAGEN)), filtered using a 40 µM filter (BD Biosciences), and
incubated on ice in the dark for 20 min. Samples were run on a BD FACS Calibur (BD
Biosciences) and analyzed using FlowJo.
Click-iT™ Plus EdU Alexa Fluor™ 488 Flow Cytometry Assay
Cells were incubated with EdU (5-ethynyl-2’-deoxyuridine) for 24 hours and
harvested following the kit protocol. Briefly, cells were trypsinized, spun down, fixed with
4% paraformaldehyde, washed with PBS, and incubated with the dye in a saponin based
buffer for 30 min in the dark. This was followed by flow cytometry on BD FACS Calibur
and analyses on FlowJo.
Proteome Profiler Human Angiogenesis Array
Xenograft tumors were lysed in PBS containing protease inhibitors and
processed according to the kit protocol. The lysates were incubated with a series of
buffered protein base solutions on a rocking platform, before being incubated with the
antibody cocktail and left overnight. The next day, membranes were washed, incubated
with HRP-Streptavidin containing buffer, and x-ray exposure was carried out using
chemiluminescent agents. ImageJ software was used to analyze the intensities of the
dot blot generated from the array and a heatmap was plotted using GraphPad Prism.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were conducted using GraphPad Prism 7.0. All error bars
represent mean ± S.E.M. One-way ANOVA with Tukey’s multiple comparisons test was
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used unless otherwise specified. Significance was defined as *p < 0.05, **p < 0.01, ***p
< 0.001.
KEY RESOURCES TABLE
REAGENT or RESOURCE
Antibodies

SOURCE

IDENTIFIER

ARG2

Santa Cruz

sc20151

b-actin

Santa Cruz

sc47778

mTOR

Santa Cruz

sc1549

ASS1

Abcam

ab124465

ASS1

Santa Cruz

s c-99178

ASL

Sigma-Aldrich

HPA016646

ODC1

Abcam

ab126590

OAZ1

Abcam

ab85221

CD31

Abcam

ab28364

Ki67

BD Biosciences

#550609

LAMP

BD Biosciences

#555803

phospho-p70 S6 Kinase (Thr389)

Cell Signaling

#9234

p70 S6 Kinase

Cell Signaling

#2708

b-Tubulin

Cell Signaling

#2146

phospho-4E-BP1 (Ser65)

Cell Signaling

#9451

phospho-histone H3

Cell Signaling

#3475S

4E-BP1

Cell Signaling

#9452

phospho-Akt (Thr308)

Cell Signaling

#13038

Akt

Cell Signaling

#9272

p21

Cell Signaling

# 2947S

cleaved caspase 3

Cell Signaling

# 9661S

phospho-Tuberin/TSC2 (Ser939)

Cell Signaling

#3615
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tuberin/TSC2

Cell Signaling

#3612

EAAT1

Cell Signaling

#5684

RagB

Cell Signaling

#8150

HSP90

Cell Signaling

#4874S

anti-rabbit IgG HRP-linked

Cell Signaling

#7074

anti-mouse IgG HRP-linked

Cell Signaling

#7076

IRDye 800CW conjugated anti-rabbit

Li-COR Biosciences

#926-32211

IRDye 800CW conjugated anti-mouse

Li-COR Biosciences

#926-32210

AlexaFluor 680 conjugated anti-rabbit

Life Technologies

#A21109

AlexaFluor 680 conjugated anti-mouse

Life Technologies

#A21058

Chemicals, Peptides, and Recombinant Proteins
DMEM

Life Technologies

11965-084

Pen/Strep

Life Technologies

15140-122

HK-2 Keratinocyte SFM Media

Life Technologies

10724-011

SILAC Flex DMEM

Life Technologies

A24939-01

DMEM for Silac

Life Technologies

88364

Glucose-free DMEM

Life Technologies

11966-025

Glutamine

Life Technologies

25030-081

Accutase

Life Technologies

A1110501

Standard FBS

Gemini

900-108

Dialyzed FBS

Gemini

100-108

U-13C6-Glucose

Cambridge Isotopes

CLM-1396

15

N2-Glutamine

Cambridge Isotopes

NLM-1328

15

N4-Arginine

Cambridge Isotopes

NLM-396-PK

Glucose

Sigma Aldrich

G8270

Putrescine

Sigma Aldrich

P5780

Spermidine

Sigma Aldrich

S0266
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Spermine

Sigma Aldrich

S4264

Ornithine

Sigma Aldrich

O6503

Aspartate

Sigma Aldrich

A7219

Lysine

Sigma Aldrich

L5501

Arginine

Sigma Aldrich

A8094

Phenol Red

Sigma Aldrich

P0290

WST-1

Sigma Aldrich

5015944001

Adenosine

Sigma Aldrich

A4036

Guanosine

Sigma Aldrich

G6264

Thymidine

Sigma Aldrich

T1895

Cytidine

Sigma Aldrich

C4654

Enhanced chemiluminescent substrate

Perkin Elmer

NEL105001EA

Matrigel matrix

Corning

354234

BioServ Dox Diet (200mg/kg)

Fisher Scientific

S3888

RNeasy Mini kit

Qiagen

#74104

High Capacity RNA-to-cDNA kit

Applied Biosystems

#4368814

Arginase Activity Assay kit

Abnova

KA1609

Urea Colorimetric Assay kit

Biovision

K375-100

QuikChange II mutagenesis kit

Agilent

#200521

Click-iT™ Plus EdU Alexa Fluor™ 488 Flow
Cytometry Assay Kit

Life Technologies

C10633

Proteome
Array Kit

R & D Systems

ARY007

HK-2

ATCC

CRL-2190

769-P

ATCC

CRL-1933

786-0

ATCC

CRL-1932

Critical Commercial Assays

Profiler

Human

Angiogenesis

Experimental Models: Cell Lines
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A498

ATCC

HTB-44

Charles River

#201

This paper

N/A

This paper

N/A

This paper

N/A

ACTB

Life Technologies

HS01060665_G
1

18S

Life Technologies

HS03928985_G
1

ASS1

Life Technologies

HS01597989_G
1

ARG2

Life Technologies

HS00982833_M
1

ASL

Life Technologies

Hs00902699_M
1

pLKO.1 Scramble

Addgene

17920

Human excitatory amino acid transporter 1
cDNA

Addgene

32813

Experimental Models: Organisms/Strains
Mouse: NIH III nude, female homozygous
Oligonucleotides
ARG2 sgRNA
Forward:
caccgGAAGAAATCCGTCCACTCCG
Reverse:
aaacCGGAGTGGACGGATTTCTTC
ASS1 sgRNA
Forward:
caccgCAGCCACACGAGGATGCACG
Reverse:
aaacCGTGCATCCTCGTGTGGCTG
ODC1 sgRNA
Forward:
caccgGAAGGGGCTTTACATGTGCG
Reverse:
aaacCGCACATGTAAAGCCCCTTCC

Recombinant DNA

45

pLJM1-Flag-RagBGTP-Q99L

Addgene

19315

pCDNA3-FLAG-MTOR-R2505P

Addgene

69015

pCDNA3-FLAG-MTOR-L1460P

Addgene

69006

LentiCRISPR v2

Addgene

52961

ARG2 SH-1

GE Dharmacon

TRCN00000510
18

ARG2 SH-2

GE Dharmacon

TRCN00000510
20

ASS1 SH-3

GE Dharmacon

TRCN00000455
54

ASS1 SH-4

GE Dharmacon

TRCN00000455
53

ASL ShRNA

GE Dharmacon

RHS3979201794747

pCDH-CMV-MCS-EF1-Puromycin

System Biosciences

CD510B-1

ARG2 cDNA

System Biosciences

MHS6278202800846

ASS1 cDNA

System Biosciences

MHS1010202694229

OAZ1 cDNA

System Biosciences

MHS6278202858287

PDXK cDNA

System Biosciences

MHS6278202827839

ASL cDNA

System Biosciences

MHS6278202755499

GraphPad Prism 8.0

GraphPad Software

https://www.grap
hpad.com/scient
ificsoftware/prism/

Spheroid macro

ImageJ

Ivanov
2014

Software and Algorithms
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CHAPTER 3: RESULTS

ccRCC Distinguished by Loss of Urea Cycle Enzymes
We employed metabolic gene set and direct metabolomic analyses of
matched human ccRCC tumor and adjacent healthy kidney samples to identify
the most significantly suppressed metabolic pathways in renal cancers (Li et
al., 2014). These determined that genes encoding multiple urea cycle
enzymes, including arginase 2 (ARG2), argininosuccinate synthase 1 (ASS1),
and argininosuccinate lyase (ASL) (Figures 2A and 2B) were, along with those
encoding carbohydrate storage enzymes (Li et al., 2014), the most significantly
downregulated in ccRCC. Data from The Cancer Genome Atlas (TCGA) also
revealed ARG2 and ASS1 copy number loss in 38% and 24% of ccRCC
patients, respectively, and copy number gain of ASL in 40% (Figure 2C). Of
note, ARG2 copy number loss is accompanied by ASS1 deletion in
approximately 40% of ARG2-deficient ccRCCs (n=184), and ARG2 and ASS1
mRNA expression in multiple cohorts was lower in ccRCC tumors compared to
normal kidney, irrespective of disease stage (Figures 2D, 3A, and 3B).
Importantly, combined ARG2 and ASS1 loss in ccRCC tumors correlated with
a nearly three-year reduction in patient survival, compared to patients whose
tumors retained wild type ARG2 and ASS1 copy number (Figure 3E). These
differences are reflected in markedly reduced ARG2 and ASS1 protein
abundance in ccRCC tumors as assessed by immunohistochemistry (IHC)
staining of primary ccRCC tissue (Figure 2F, and 3C) and primary sample
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cores (Figure 3D). Loss of ARG2 and ASS1 could reflect a less “differentiated”
phenotype or reentry into the cell cycle by ccRCC cells. We assessed ARG2
and ASS1 expression in HK-2 cells arrested at different cell cycle stages using
pharmacological approaches (Figure 3E-F). However, ARG2 and ASS1 mRNA
levels were actually elevated in G1/S phases, relative to G2 and M. ARG2 and
ASS1 protein levels were similarly increased during S phase (Figure 3F).
These data indicate that ARG2 and ASS1 expression is not downregulated
during proliferation, suggesting that their under expression in ccRCC is not a
consequence

of

cellular dedifferentiation The abundance of multiple

metabolites in the “urea cycle, arginine, and proline metabolism” KEGG
classification was also significantly altered, as arginine, proline, and urea levels
were all lower in ccRCC tumors compared to the normal kidney (Figure 2G). In
particular, the nitric oxide synthase inhibitor dimethylarginine was reduced in
ccRCC tumors, which may contribute to robust vascularization characteristic of
ccRCC (Aziz et al., 1994; De Gennaro Colonna et al., 2009). Given the high
frequency of gene copy number loss, reduced mRNA and protein expression,
altered urea cycle metabolite levels, and correlative survival differences, we
further explored the role of ARG2 and ASS1 as potential metabolic
suppressors of ccRCC tumorigenesis.
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Figure 2. Urea Cycle mRNA, Protein, and Metabolite Alterations in ccRCC
A.
Metabolic gene set analysis of RNAseq data provided by the TCGA, classified
according to KEGG (Li et al., 2014). Generated metabolic gene sets were ranked based
on their median fold expression changes in ccRCC tumor (n=480) vs. normal tissue
(n=69) and plotted as median ± median absolute deviation.
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B.
The complete urea cycle as configured in the liver. Inset: TCGA-derived gene
expression changes of urea cycle enzymes in ccRCC.
C.
Copy number variation and mutational burden of urea cycle enzymes in 184
ccRCC tumors (data from TCGA).
D.
ARG2 and ASS1 mRNA levels in ccRCC (TCGA). ***p <0.001, Welch’s t-test.
E.
Copy number variation in ARG2 and ASS1 in ccRCC patients. Kaplan-Meier
survival
analysis of copy number loss in ARG2 and ASS1 (from TCGA data). Mantel-Cox logrank test was performed.
F.
Representative immunohistochemistry images of ARG2 or ASS1 protein in
primary ccRCC, N = normal, T = tumor. Scale bars represent 100 µm
G.
Violin plot of urea cycle metabolite abundance in primary ccRCC combining two
independent datasets, n = 158 (Hakimi et al., 2016; Li et al., 2014). Data are displayed
as the log2 tumor/normal fold change and are pseudo-colored according to the intensity
of the fold change in median. The internal bars represent the mean and SD of 158
tumor/normal pairs.
Abbreviations: ARG2, arginase 2; ASS1, argininosuccinate synthase 1; ORNT1,
ornithine translocase 1 (also called SLC25A15); CPS1, carbamoylphosphate synthase 1;
OTC, ornithine transcarbamylase.
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Figure 3. Urea Cycle mRNA, Protein, and Metabolite Alterations in ccRCC
A.
ARG2 and ASS1 mRNA levels in ccRCC segregated by disease stage (TCGA).
B.
qRT-PCRanalysis of primary matched normal kidney and ccRCCs (obtained from
the Collaborative Human Tissue Network as an independent cohort) also demonstrate
reduced ARG2 and ASS1 expression in tumors relative to health kidney cortex.
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C.
Additional immunohistochemistry images of ARG2 or ASS1 protein in primary
ccRCC, N = normal, T = tumor. Scale bars represent 200 µm.
D.
Immunohistochemistry staining on primary ccRCC tissue microarrays (US
Biomax) and quantification of staining intensity. N = normal, T = tumor.
E.
Flow cytometry plots of HK-2 cells arrested at various cell cycle phases using the
indicated drug treatments.
F.
ARG2 and ASS1 mRNA and protein abundance in HK-2 cells across various cell
cycle phases; data normalized to an asynchronous population of cells (A). Error bars
represent SEM of 3 replicates.
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ARG2 and ASS1 Re-expression suppress ccRCC cell growth
To assess the functional consequences of decreased ARG2 and ASS1
expression in ccRCC, we compared control HK-2 immortalized proximal tubule
kidney epithelial cells, which retain ARG2 and ASS1, to several ccRCC cell
lines that lack detectable ARG2 and/or ASS1 protein (Figure 4A). Whereas all
ccRCC cell lines lack significant ARG2 expression (consistent with primary
patient samples), only a subset (786-O, A498, RCC10, UOK101) exhibit
decreased ASS1 abundance when cultured in vitro, and 786-O and A498 cells
were consequently chosen for the majority of subsequent analyses. Stable
knockdown of ARG2, ASS1, or both ARG2 and ASS1 (Double KD), mRNAs
(Figure 4B) increased proliferation of control HK-2 cells in tissue culture (2D
growth; Figure 4C) and anchorage-independent 3D soft agar growth assays
(Figure 4D); moreover, the 3D growth effects were enhanced when both ARG2
and ASS1 were reduced simultaneously. HK-2 cells were grown in low
serum/low glucose conditions (1% FBS, 1 mM glucose) to mimic nutrient
availability typical of the tumor microenvironment. These results were
subsequently confirmed using clonally selected HK-2 cells with CRISPR/Cas9
mediated deletion of ARG2 or ASS1 (Figure 4E). Remarkably, loss of a single
urea cycle enzyme (i.e. ARG2 or ASS1) was sufficient to give normal kidney
cells a significant growth advantage. Conversely, ectopic ARG2 and/or ASS1
re-expression in polyclonal 786-O and A498 ccRCC cells reduced 3D spheroid
volume, the number of cells per spheroid, soft agar colony formation, and 2D
growth (Figures 6A-B, and 5A). Interestingly, ARG2 re-expression only
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modestly inhibited the growth of UMRC2 ccRCC cells (Figure 5B), which may
reflect the presence of endogenous ASS1 and slightly elevated baseline ARG2
in these cells, compared to other ccRCC cell lines (Figure 4A). Of note, ARG2
and ASS1 re-expression was carefully titrated in an attempt to match protein
levels in HK-2 cells throughout these studies (Figures 6A and 5A-B).
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Figure 4. Loss of ARG2 and ASS1 Enhances Proliferation of Normal
Kidney Cells
A.
ARG2 and ASS1 protein levels in HK-2 kidney epithelial and various
ccRCC cell lines. Tubulin or actin served as loading controls.
B.
Upper panel: short hairpin-mediated knockdown of ARG2, ASS1, or
both
simultaneously (Double KD) in HK-2 cells. Tubulin or actin served as loading
controls. Lower panel: mRNA levels after knockdown with two independent
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hairpins. Error bars represent SEM of 3 independent replicates.
C-D. Knockdown of ARG2 or ASS1 augments HK-2 cell growth in (C) 2D
growth and (D) 3D soft agar colony formation assays. Double KD experiments
employed ARG2 SH-1 and ASS1 SH- 4. In (C), cells were grown in 1% FBS
and 1 mM glucose media (changed every 2 days). Error bars represent SEM
from 3 replicate wells. **p < 0.01, ***p < 0.001, one-way ANOVA with Tukey’s
multiple comparisons test.
E. Clonally selected CRISPR/Cas9-mediated ARG2-/- or ASS1-/- HK-2 cells
demonstrate enhanced growth. Guide RNA against EGFP was used as a
control, ns = non-specific band. Cells were grown in 1% FBS and 1 mM
glucose media (changed every 2 days). Error bars represent SEM of 16
replicate wells.
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Figure 5. ARG2 Suppresses ccRCC Growth in vitro
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A.
Left panel: Ectopic expression of ARG2 and/or ASS1 in A498 ccRCC cells.
Numbers below ARG2 and ASS1 western blots represent quantified fold change in
protein compared to normal HK-2 cells. Right panel: A498 growth assay in complete
media. Error bars represent SEM of 3 replicates.
B.
Left panel: Ectopic expression of ARG2 in UMRC2 ccRCC cells. Right panel: 3D
soft agar colony forming assay of UMRC2 cells. Error bar represents SEM of 3
replicates, Welch’s t-test.
C.
786-O, A498, and HK-2 cell growth assay in complete versus arginine deficient
media.
D.
786-O and HK-2 growth assays in complete versus arginine depleted conditions
(50-fold decrease compared to normal culture conditions).
E.
Ectopic expression of wild type ARG2 and ARG2 H160F mutant protein in 786-O
cells. Densitometry analysis of Li-COR captured images indicate that ARG2 mutant
protein is expressed at 75% of wild type ARG2 protein. Lane 4 has half the amount of
wild type ARG2 protein loaded for reference. *p < 0.05, **p < 0.01, ***p < 0.001, a oneway ANOVA with Tukey’s multiple comparisons test was conducted for each dataset
unless otherwise specified.
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ARG2 Suppresses ccRCC Growth via its Enzymatic Activity

To confirm that exogenously expressed ARG2 and ASS1 proteins are
catalytically active, we performed liquid chromatography-mass spectrometry
(LC/MS) to measure arginine, citrulline, and aspartate levels in transduced
786-O ccRCC cells. As expected, arginine levels were significantly reduced
upon ARG2 expression, as were both citrulline and aspartate upon ASS1
expression (Figure 6C). Combined ARG2 and ASS1 expression decreased
the abundance of all three urea cycle metabolites, most notably citrulline and
aspartate. We reported previously that a key metabolic enzyme, FBP1, has
catalytic activity-independent mechanisms of tumor suppression in ccRCC (Li
et al., 2014). To test whether this was true for ARG2, we generated a
missense mutation (ARG2 H160F) that abolished enzymatic activity (Figure
6D), consistent with previous reports (Xiong et al., 2014). In a 3D spheroid
growth assay, expression of wild type ARG2 dramatically reduced ccRCC
spheroid volume and the number of cells per spheroid, whereas ARG2
H160F failed to suppress spheroid growth (Figure 6E) and soft agar colony
formation (Figure 6F). These data clearly demonstrate that ARG2 catalytic
activity is required for ccRCC growth suppression, in contrast to FBP1 (Li et
al., 2014). Loss of multiple urea cycle enzymes would be predicted to render
ccRCC cells dependent on exogenous arginine for proliferation. Indeed, 786O and A498 cells appear to be arginine auxotrophs, based on the absence of
growth in arginine deficient media (Figure 5C). These findings are consistent
with Yoon et al., who previously reported that kidney cancer cells exhibit low
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ASS1 levels and sensitivity to arginine deprivation (Yoon et al., 2007).
However, unlike hepatocytes, normal kidney cells do not express all urea
cycle enzymes (see Figure 7C). Therefore, they would not be expected to
survive total deprivation of exogenous arginine either (Figure 5C). ccRCC
cells suggesting that they may be less sensitive to arginine depletion, as
shown for 786-O cells grown in 50X less arginine concentrations (Figure 5D,
left panel).
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Figure 6. ARG2 Enzymatic Activity is Required for ccRCC Growth
Suppression
A.
Left panel: Ectopic expression of ARG2 and/or ASS1 in 786-O ccRCC
polyclonal populations. Numbers below ARG2 and ASS1 western images
represent the quantified fold change in protein compared to normal HK-2
cells. Right panel: 3D spheroid growth assay of 786-O cells. After three
weeks of growth, spheroid volume was measured via microscopy and the
number of cells per spheroid was counted after accutase digestion of
spheroids to a single cell suspension. Error bars represent SEM of three
independent replicates containing 12 spheroids each.
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B.
Soft agar growth assays of 786-O ccRCC cells. Error bars represent
SEM of 5 replicate wells.
C.
LC/MS quantitation of arginine, citrulline, and aspartate in 786-O cells
stably expressing urea cycle enzymes. Error bars represent SEM of 4
replicates.
D.
Expression and activity of wild type (WT) and H160F mutant ARG2
and
E.
786-O spheroid growth assay demonstrating ARG2 catalytic activitydependent growth suppression. Error bars represent SEM of 3 independent
replicates containing 12 spheroids each.
F.
786-O soft agar colony growth assay depicting ARG2 catalytic activitydependent growth suppression. Error bars represent SEM of 3 replicate wells.
*p < 0.05, **p < 0.01, ***p < 0.001, a one-way ANOVA with Tukey’s multiple
comparisons test was conducted for each dataset unless otherwise specified.
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Figure 7. ARG2 Suppresses ccRCC Growth in vivo
A.
786-O xenograft tumor weight (of tumors shown in Figure 4A). At the
end of each assay, mice were sacrificed and, tumors dissected and weighed.
B.
ARG2 activity in xenograft tumors was confirmed by measuring urea
concentration. Urea was measured in four pairs of matched control and urea
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cycle enzyme-expressing ccRCC tumors. *p
< 0.05, **p < 0.01, ***p < 0.001, Welch’s t-test.
C.
Schematic representation of the “urea shunt” in renal epithelial cells.
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ARG and/or ASS1 suppress ccRCC growth in vivo, independent of mTORC1
activity and nucleotide synthesis
We evaluated the effects of ARG2 and/or ASS1 expression on ccRCC
xenograft tumor growth in nude mice, as a fully accurate, autochthonous
murine ccRCC model has only recently been described (Nargund et al., 2017).
Ectopic ARG2 expression in 786-O ccRCC xenografts reduced tumor growth in
vivo, which was further suppressed by co-expression of ARG2 and ASS1
(Figures 8A and 7A). Compared to ARG2, ASS1 expression produced a
relatively modest effect on tumor volume at later time points (days 38-40)
(Figure 8A), although the reduction in tumor mass at the experimental endpoint
failed to achieve statistical significance (Figure 7A). It is noteworthy that ARG2
H160F failed to significantly suppress either tumor volume or mass (Figures
8A, 7A), consistent with in vitro assays described in Figure 6. Interestingly, the
ASS1-,

ARG2-,

and

ASS1/ARG2-expressing

tumor

cohorts

exhibited

decreased tumor cell proliferation and some evidence of reduced mTORC1
activity (Figures 8B-C), and ARG2- and combined ARG2/ASS1- expressing
tumors displayed the expected patterns of altered urea concentration (Figure
7B). We then focused primarily on ARG2, as it exhibited the most consistent
and robust suppression of growth and mTORC1 activity in multiple ccRCC cell
lines both in vitro and in vivo (e.g. Figures 6A, 8A ,8C, and 7A). Moreover, the
urea “cycle” is configured somewhat differently in the kidney than the liver,
where ARG2 resides in the mitochondria rather than the cytoplasm in renal
cells (compare Figures 2B and 7C), rendering ARG2 mediated reactions
somewhat biochemically “independent”. An unbiased metabolomics analysis to
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assess the impact of expressing ARG2 in ccRCC xenograft tumors was
performed (Figure 8D). ARG2 expression caused striking widespread
metabolic changes, most notably significant decreases in the concentration of
multiple amino acid, lipid, nucleotide, and vitamin/cofactor metabolites. In
particular, ARG2 expression decreased the abundance of 10 naturally
occurring amino acids (Figure 8E).
Given the requisite role of amino acids in controlling the activity of the
mechanistic target of rapamycin (mTOR) nutrient sensing pathway (Gonzalez
and Hall, 2017), we postulated that ARG2 might suppress ccRCC growth by
decreasing amino acid abundance and thus, mTORC1 activation. Indeed,
mTORC1 activity was reduced in xenograft tumors expressing either ARG2,
ASS1, or both enzymes, as determined by phospho-S6K1, phospho-S6,
phospho-4E-BP1 and phospho-ULK-1 levels (Figures 8C, 9A, and 9B). The
phosphorylation status of these mTORC1 substrates was not accompanied by
changes in the activity of upstream regulators Akt and TSC2 (Figure 9A), which
respond to growth factors instead. However, several experimental results
indicated that the ARG2-dependent phenotypes we observed are (at least in
part) mTORC1- independent. For example, we initially hypothesized that
elevated citrulline in ASS1-deficient ccRCC cells might activate mTORC1, as
previously reported (Breuillard et al., 2015; Cynober et al., 2013; Le Plenier et
al., 2012; Moinard and Cynober, 2007); however, exogenous citrulline (in
contrast to leucine) had no consistent effect on S6 and 4E-BP1
phosphorylation in 786-O cells, even when present at supra-physiological
levels (Figure 9C).
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An alternative model posited that ARG2 and ASS1 expression could
alter the subcellular distribution of mTORC1, which responds to amino acid
stimulation by translocating to the lysosomal surface in a RAG GTPasedependent manner (Bar-Peled and Sabatini, 2014). However, expression of
these enzymes in ccRCC cells had no effect on subcellular mTORC1
lysosomal localization (Figure 9D). We also introduced two constitutively active
mTORC1 mutants (R2505P and L1460P; (Grabiner et al., 2014)) into 786-O
cells with and without ARG2 reconstitution. Figure 9D indicates that both
constructs override ARG2-mediated mTORC1 suppression, based on
phospho-S6 levels. Intriguingly, mTORC1 R2505P and L1460P, if anything,
suppress growth of control cells in soft agar colony formation assays, while
failing to fully restore the growth of ARG2-expressing cells (Figure 9E). A direct
comparison is provided when one assesses the vector plus mTORC1 R2505Ptransduced cells to ARG2 plus mTORC1 R2505P- expressing cells. These
observations can be explained by suppression of basal autophagy (which may
be active in 3D growth assays where colonies develop O2/nutrient gradients)
by constitutively active mTORC1. We also examined whether ARG2 instead
modulates mTORC1 through global changes in amino acid availability, by
expressing a constitutively active form of RagB, RagB Q99L (RagBGTP), which
confers high levels of mTORC1 activity (Sancak et al., 2008), even in the
absence of amino acids (see Figure 9G). We reasoned that if ARG2
suppresses ccRCC tumor growth by depleting amino acids, thereby reducing
mTORC1 activity, constitutively active RagBGTP should rescue ARG2dependent tumor growth suppression. Unexpectedly, the growth of 786-O
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ccRCC xenograft tumor cells co-expressing both ARG2 and RagBGTP was
equivalent to those expressing ARG2 alone, indicating that mTORC1 is not
solely responsible for ARG2-dependent ccRCC growth suppression (Figure
9H).
Decreased expression of ASS1 and ASL has been reported in other
cancers (Huang et al., 2013; Kobayashi et al., 2010; Rabinovich et al., 2015),
although ccRCC appear to have suppressed additional urea cycle enzymes,
especially ARG2. Of note, Rabinovich et al. demonstrated that ASS1
deficiency increases cytoplasmic aspartate levels (Rabinovich et al., 2015),
which are critical for maintaining pyrimidine biosynthesis in multiple cancer cell
lines (Birsoy et al., 2015; Sullivan et al., 2015). Specifically, ASS1-deficient
sarcoma cells divert aspartate away from the urea cycle to support de novo
nucleotide production and DNA replication (Rabinovich et al., 2015). Because
ARG2-expressing xenograft tumors exhibited reduced aspartate levels (Figure
8E), we explored the possibility that supplying exogenous aspartate might
reverse ARG2-dependent growth suppression, given that ARG2 re-expression
also resulted in decreased nucleotide abundance (Figure 8D). We employed
the 3D spheroid assay for this purpose, where ARG2 re-expression results in
decreased spheroid volume (Figure 11A and B), mimicking reduced in vivo
tumor growth (Figure 8A). However, supplementation with supra- physiological
levels of aspartate (20 mM) was incapable of increasing cell proliferation in
ARG2 reconstituted 786-O spheroids (Figure 11C). 786-O cells express
relatively low levels of the glutamate-aspartate transporter SLC1A3, also
known as the excitatory amino acid transporter, or EAAT1 (data not shown),
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which could result in poor aspartate transport (Birsoy et al., 2015). We
therefore generated 786-O cells stably expressing human SLC1A3/hEAAT1
and cultured them in media containing 150 µM aspartate in a 2D growth assay,
along with vector controls (Figure 11D). If anything, SLC1A3/hEAAT1
overexpression resulted in decreased rates of ARG2/786-O cell proliferation
relative to control cells. To confirm that 786-O cells import aspartate from
extracellular medium, cells expressing both exogenous ARG2 and the
aspartate transporter hEAAT1 were cultured with 13C-labelled aspartic acid for 6
hours and intracellular

13

C-aspartate measured using GC/MS. In the results

shown in Figure 11E, we observed that 786-O cells take up aspartate
irrespective of ARG2 expression, although exogenous hEAAT1 enhances
aspartate transport by 30-40X in both settings. Therefore, the results
presented in Figure 11C and S5D reflect cells importing exogenous aspartate,
especially when expressing hEEAT1.
Kim et al. recently determined that increased expression of the urea
cycle enzyme carbamoyl phosphate-1 in Kras/LKB1 mutant lung cancer cells is
essential to maintain their intracellular pyrimidine pools, DNA synthesis, and
genome integrity (Kim et al., 2017). However, culturing ARG2/786-O cells in
various concentrations of cytidine, thymidine, or all four deoxyribonucleosides
failed to change 3D spheroid growth rates over a two-week period (Figure 11EF). Overall, these results strongly suggest that 1) decreased mTORC1
signaling, aspartate levels, and/or nucleotide availability are not sufficient to
fully account for the growth suppressive effects of ARG2 in ccRCC, and 2)
ARG2’s role as a metabolic tumor suppressor is dependent on its catalytic
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activity.
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Figure 8. ARG2 Suppresses in vivo Tumor Growth and Leads to Multiple Metabolic
Changes
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A.
786-O xenograft tumor growth in nude mice, where cells re-express ASS1, wild
type ARG2, ARG2 H160F mutant, or both ASS1 and ARG2 (n = 10 mice in each cohort,
except for n=5 for the ARG2 H160F study).
B.
Immunohistochemistry staining for Ki67 as a marker of proliferation in xenograft
tumors expressing urea cycle enzymes, high power fields (HPF). (
C.
mTORC1 activity in ARG2- or ASS1-expressing xenograft tumors, as assessed
by the mTORC1 targets phospho-S6K1, phospho-S6, and phospho-4E-BP1.
D.
Unbiased metabolomic analysis of control or ARG2 expressing xenograft tumors,
n = 7 for each cohort. ARG2 expression causes robust global reductions in several
categories of metabolites, especially lipids, nucleotides, and biosynthetic co-factors.
E.
Amino acid abundance in 786-O xenograft tumors (n = 7). Data are represented
as the percent change in amino acid, after normalization to each corresponding control
tumor. *p < 0.05, **p < 0.01, ***p < 0.001, Welch’s t-test was used for each dataset.
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Figure 9. mTORC1 Not Solely Responsible in ARG2-dependent Growth
Suppression
A-B. mTORC1 activity is reduced upon combined ARG2 and ASS1 re-expression in
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xenograft tumors, as assessed by the mTORC1 targets phospho-S6K1 and phospho4E-BP1 (A) and phospho-ULK1 (B).
C.
Citrulline does not activate mTORC1 in ccRCC. 786-O ccRCC were treated with
5 mM citrulline for the indicated times, after which cells were lysed and assessed for
mTORC1 activity. Numbers below the phospho-S6 western blot represent levels relative
to total S6 protein at time 0. Leucine treatment was used as a positive control for
mTORC1 activation.
D.
786-O cells with ectopic expression of constitutively active mTORC1 point
mutants (R2505P and L1460P) override ARG2-mediated suppression of mTORC1 target
phospho-S6.
E.
Soft agar colony formation assay with 786-O cells expressing vector or ARG2,
and constitutively active mTORC1 mutants. Error bars represent SEM of 3 replicate
wells.
F.
Immunofluorescence imaging of mTORC1 (red) and LAMP (green) in 786-O
cells, indicating no consistent change in mTOR localization at LAMP+ lysosomes upon
ARG2 and/or ASS1 re- expression. Nuclei, stained with DAPI, appear blue. Scale bar =
20 µm. Inserts represent 5X magnification of a portion of each panel.
G.
786-O cells stably expressing either ARG2 or RagBGTP in response to amino
acid deprivation and re-stimulation. Experiment and exact conditions replicated from
(Sancak et al., 2008). RagBGTP renders 786-O cells insensitive to amino acid
deprivation. (H) 786-O xenograft tumor growth in ARG2 or ARG2 + RagBGTP
expressing cells. Tumor weight was measured following animal sacrifice at the end of
each assay.
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ARG2 Suppresses ccRCC Growth via Depletion of the Essential Cofactor
Pyridoxal Phosphate
To define alternative mechanisms whereby urea cycle enzymes
influence ccRCC tumor growth, we focused on the downstream metabolites
altered by ARG2 activity, which hydrolyzes arginine to generate ornithine and
urea. Ornithine has multiple biochemical fates and can be converted by
mitochondrial ornithine aminotransferase (OAT) to glutamate-gammasemialdehyde, a substrate for the synthesis of both glutamate and proline
(Figure 10A). 15N4- arginine tracing in HK-2 cells revealed that M+1 enrichment
of both glutamate and proline was abolished upon ARG2 knockout (Figure 10B,
left panel). Conversely, ectopic ARG2 expression in 786-O ccRCC cells
dramatically increased 15N4-arginine incorporation into glutamate and proline
(Figure 10B, right panel), suggesting that ARG2 directly controls the levels of
downstream ornithine metabolites by increasing substrate availability for OAT.
Of note, the absolute concentration of glutamate and ornithine did not change
in these experiments (Figure 13A).
An alternative metabolic fate for ornithine is decarboxylation by
ornithine decarboxylase (ODC) to generate the polyamine putrescine (Figure
10A). Interestingly, both OAT and ODC require the cofactor pyridoxal-5’phosphate (PLP) for catalysis. PLP is a vitamin B6 derivative involved in
approximately 4% (~140) of all known cellular enzymatic reactions (Percudani
and Peracchi, 2003). Vitamin B6 encompasses six various inter-converted
forms, including pyridoxine (PN), pyridoxal (PL), pyridoxamine (PM), and their
phosphorylated versions (Figure 10C); however, only PLP is the bioactive
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cofactor used in enzymatic reactions (Galluzzi et al., 2013). Phosphorylation of
the various B6 precursors to generate active PLP requires pyridoxal-5’phosphate kinase (PDXK), the expression of which is reduced across all
stages of ccRCC (Figure 10D).
As PLP is a cofactor in numerous eenzymatic reactions, we
hypothesized that small perturbations in PLP levels could have significant cell
growth effects. Furthermore, because ARG2 supplies the ornithine substrate
for ODC and OAT (Figure 10A), enhanced reaction rates of these enzymes in
ARG2-expressing cells might deplete PLP pools. Ectopic ARG2 expression
significantly reduced the concentration of PLP, as expected, with no effect on
the precursors PL, PN, etc. in 786-O ccRCC cells (Figure 10E, right panel).
Conversely, deletion of ARG2 in HK-2 cells produced significantly elevated
concentrations of PLP (Figure 10E, left panel), demonstrating that ARG2
activity modulates the pool of available PLP.
In complementary experiments, we ectopically expressed PDXK to
increase PLP levels (Figure 10F and 10G), which rescued all ARG2-mediated
growth defects, including slowed 2D proliferation (data not shown), decreased
3D soft agar colony numbers (Figure 10H), and reduced colony size (Figure 10I).
This approach was adopted because PLP is too labile to add to semisolid culture
media as a supplement (data not shown). To demonstrate that ectopic PDXK
was having the predicted effects on intracellular levels of pyridoxine pathway
components, we employed LC/MS for their quantification in ARG2- and PDXKexpressing 786-O cells (see Experimental Procedures). Certain pyridoxal
derivatives (PM, PNP, PMP) were difficult to accurately measure, as they exist
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at the borderline of detection in our experimental system. Nevertheless,
expressing PDXK in 786-O cells reduced intracellular levels of the PLP
precursors PN, PL, and PM (Figures 10G and 13B). Interestingly, steady-state
PLP levels were also decreased in PDXK-expressing vector control cells
(Figure 10G), likely due to PLP consumption by multiple intracellular reactions.
However, ectopic PDXK expression increases PLP levels in ARG2-expressing
cells, albeit not to the levels observed in controls (Figure 10G). In aggregate,
these data support the hypothesis that ARG2 inhibits ccRCC growth, at least in
part, by depleting the intracellular PLP cofactor pool, resulting in reduced
production of amino acids and numerous other metabolites.
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Figure 10. ARG2 Suppresses ccRCC Growth via Depletion of Pyridoxal Phosphate
(PLP)
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A.
Schematic representation of 15N4-Arginine labeling into glutamate and proline
synthesis. Ornithine decarboxylase (ODC) and ornithine aminotransferase (OAT)
reactions and their requirement for pyridoxal phosphate (PLP) as a cofactor are
highlighted. Closed red circles represent heavy nitrogen (15N) while open black circles
represent carbon atoms (12C).
B.
ARG2 controls the downstream synthesis of glutamate and proline. HK-2 (left
panel) or 786-O cells (right panel) incubated with 15N4-Arginine. Synthesis of glutamate
and proline from arginine results in one -15N incorporation (M1 enrichment), represented
as atom percent excess (APE). Error bars represent SEM of 3 and 5 replicates for HK-2
and 786-O, respectively.
C.
Schematic for the synthesis of PLP. Several precursor forms of pyridoxal exist
and interconverted between their phosphorylated versions; only PLP is the bioactive
cofactor.
D.
mRNA levels of pyridoxal kinase (PDXK) in ccRCC (data from TCGA). Box plots
represent 69 normal and 480 tumor samples, one-way ANOVA with Tukey’s multiple
comparisons test.
E.
ARG2 directly modulates the levels of bioactive PLP. HK-2 (left panel) or 786-O
cells (right panel) were grown in 1% FBS with 1 mM glucose for 24 hours (HK-2) or
hypoxia (0.5% O2) for 48 hours (786-O) prior to quantifying the total PL, PLP, PN, and
PM levels via LC/MS. Error bars represent SEM of 3 and 5 replicates for HK-2 and 786O, respectively.
F.
Ectopic ARG2 and/or PDXK expression in 786-O cells.
G.
PDXK overexpression alters levels of pyridoxine pathway components. 786-O
cells were cultured under hypoxia (0.5% O2) for 48 hours prior to quantifying total PL,
PLP, PN, and PM levels via LC/MS. Error bars represent SEM of 5 replicates.
H-I. PDXK expression reverses ARG2-dependent growth suppression. 3D soft agar
colony formation assay of 786-O cells ectopically expressing either ARG2 and/or PDXK.
(H) Quantification of colony number and (I) representative pictures of colony size. Scale
bar represents 25 μm. Error bars represent SEM of 6 replicate wells for each condition,
one-way ANOVA with Tukey’s multiple comparisons test. *p < 0.05, **p < 0.01, ***p <
0.001, a two-way ANOVA with Tukey’s multiple comparisons test was conducted for
each dataset unless otherwise specified.
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Figure 11. Exogenous Aspartate and Nucleosides Have No Effect
on ARG2 Expressing ccRCC Cells
A.
Matrigel-based 3D spheroid growth assay of 786-O cells.
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Spheroid volume was measured via microscopy over two weeks.
B.
Representative pictures showing spheroid volume.
C.
Exogenously provided aspartate is detrimental to ARG2 reexpressing ccRCC cells. A matrigel- based 3D spheroid growth assay
of 786-O cells was supplemented with 20 mM aspartate.
D.
Overexpression of the human glutamate-aspartate transporter,
or “excitatory amino acid transporter” (hEAAT1), in 786-O cells in
media supplemented with exogenous aspartate (Asp) failed to rescue
ARG2-mediated growth suppression in a 2D growth assay. 786-O cells
stably expressing ARG2 with and without hEEAT1 cultured in 150 μM
aspartate (where indicated), and growth assessed with a WST-1 based
assay.
13
E.
C-labelled aspartate uptake in ccRCC cells. 786-O cells with
vector or ARG2, and/or hEAAT1 were cultured with 150 M aspartic
acid for 6 hours and intracellular uptake was measured by GC/MS. SD
values represent 3 technical replicates.
F.
Exogenously provided pyrimidines do not confer a growth
advantage upon ARG2 re-expressing 786-O cells. A matrigel-based 3D
spheroid growth assay was carried out in media supplemented with the
indicated concentrations of pyrimidines (cytidine and thymidine).
G.
Exogenous nucleosides do not confer a growth advantage on
ARG2 re-expressing 786-O cells. A matrigel-based 3D spheroid growth
assay was conducted in media supplemented with 50 μM adenosine,
guanosine, cytidine or thymidine. Error bars represent SEM of 12
technical replicates.
*** p< 0.001, a one-way ANOVA with Tukey’s multiple comparison test.
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Excess Polyamine Production Upon ARG2 Expression Leads to ccRCC Growth
Suppression
We hypothesized that altered polyamine synthesis or metabolism might
also contribute to the growth suppressive effects of ARG2 expression in
ccRCC. Ornithine- derived putrescine is converted to higher order polyamines
spermidine and spermine through the addition of decarboxy-SAM-derived
aminopropyl groups (Michael, 2016) (Figure 12A). While polyamines promote
tumor progression in some contexts (Soda, 2011; Tsujinaka et al., 2011), they
cause cellular toxicity in other tumor cells (Pegg, 2013), although the precise
mechanisms by which polyamines either promote or inhibit tumor growth are
not well characterized. Treatment of 786-O ccRCC cells with exogenous
putrescine resulted in a dose-dependent toxicity, whereas putrescine had no
effect on the growth of control HK-2 cells, even at relatively high (10 mM)
concentrations (Figure 12B). To examine the sensitivity of non-ccRCC cancer
cells to exogenous polyamines, we studied prostate cancer cells (VCaP and
LnCaP), reasoning that the prostate is an important physiological source of
polyamines. Accordingly, prostate cells were cultured in the presence of 5 mM
and 10 mM putrescine and appeared to be more resistant to putrescine levels
toxic for 786-O, even when growing rapidly (Figures 12B and 15B). Putrescine
concentrations used for these experiments were chosen based on calculations
described in the Experimental Methods. In aggregate, these data suggest that
the metabolic wiring of ccRCC cells makes them particularly sensitive to
changes in polyamine concentrations.
Hypoxia has been shown to promote the cellular uptake of polyamines
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in both normal and malignant cells, downstream of HIF1a stabilization (Aziz et
al., 1994; Babal et al., 2002; Tantini et al., 2006; Tsujinaka et al., 2011). Of
note, hypoxia can also stimulate ODC expression and activity (Babal et al.,
2002). We speculated that naturally occurring tumor hypoxia and constitutive
HIF activity might commit ccRCC cells to take up potentially toxic levels of
polyamines from the microenvironment, thereby selecting for cells with lower
endogenous polyamine synthesis (Svensson et al., 2008). This hypothesis is
supported by unbiased metabolomics analyses of two independent ccRCC
cohorts (n=158 samples in total; (Hakimi et al., 2016; Li et al., 2014) that
demonstrated a marked overall elevation in putrescine and spermine
concentrations, with minor elevations in the levels of spermidine (Figure 12C).
mRNA expression data are also consistent with reduced de novo polyamine
synthesis in ccRCC cells (Figure 12A). For example, transcripts encoding
ARG2, ODC1, and spermine synthase (SMS) are expressed at lower levels in
ccRCC than normal kidney tissue (Figure 12A). Additionally, upstream
regulators of ODC, which catalzyes the committed step in polyamine synthesis,
are modulated in a manner consistent with this model. Specifically, ornithine
decarboxylase antizymes (OAZ) 1, 2, and 3 bind the ODC protein and target it
for degradation via the 26S proteasome (Tajima et al., 2016). OAZ expression is
elevated in ccRCC (Figure 12A), consistent with reduced ODC protein levels
(Figures 6D and S6B). Elevated OAZ expression in ccRCC also correlates with
worse patient survival (Figure 6E). Furthermore, expression of antizyme
inhibitor 1 (AZIN1), which regulates polyamine synthesis by binding and
inhibiting OAZ, thereby stabilizing ODC and promoting polyamine synthesis
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(Wu et al., 2015), was also reduced in ccRCC samples (Figure 12A), consistent
with reduced polyamine synthesis. Taken together, these data support the
hypothesis that altered expression of genes encoding polyamine pathway
enzymes reduces endogenous polyamine synthesis in ccRCC as an adaptive
response to the accumulation of toxic polyamines.
Metabolic tracing experiments were conducted to follow the fate of 15N4arginine in ccRCC cells with regard to downstream products such as ornithine
and putrescine (Figure 14A). Ectopic expression of ARG2 in 786-O ccRCC
cells led to robust incorporation of 15N4-arginine into M+2 ornithine and urea, as
well as the downstream metabolite M+2 putrescine (Figure 14B, bottom panel).
Conversely,

15

N4-arginine incorporation into these metabolites was markedly

reduced in ARG2-deficient HK-2 cells (Figure 14B, top panel). Ectopic ARG2
expression in 786-O cells elevated arginine-dependent putrescine synthesis
nearly 3-fold, whereas ARG2 depletion in HK-2 cells reduced this by
approximately 8-fold, independent of changes in ODC expression. Absolute
levels of putrescine in 786-O and HK-2 cells were determined to be 2-4 mM
in media lacking exogenous polyamines (Figure 13A), with ARG2 deletion
reducing levels by 8X in HK-2 cells, and ARG2 re-expression increasing
putrescine levels 4X in 786-O cells in these conditions. However, culturing the
same renal cells in exogenous 2.5 mM putrescine dramatically increased its
intracellular abundance >10-fold (Figures 14C and 15A). These findings
indicate that kidney cells actively transport large quantities of polyamines from
their microenvironment. As expected, both ARG2 expression and/or hypoxia
increased intracellular putrescine levels (Figure 14C). ARG2 expression also
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increased the levels of spermidine and spermine, although the magnitude of
this effect did not attain statistical significance. On the other hand, ARG2
knockout in HK-2 cells reduced the levels of putrescine (Figure 15A), while
hypoxia had no effect (15A), likely due to the lack of constitutive HIF activity in
a VHL wild type setting.
As stated previously, HK-2 renal epithelial cells gain a proliferative
advantage when ARG2 expression is reduced or eliminated (Figures 4C-E and
Figure 14D). To test if reduced polyamine levels contribute to this growth
advantage, we treated HK-2 cells with exogenous polyamines. CRISPR control
HK-2 cells were unaffected by exposure to increasing levels of putrescine,
spermine, or spermidine, (Figures 14D-E and 15B, left panels), while growth of
ARG2-deficient HK-2 cells was inhibited by putrescine, spermine, and
spermidine in a dose-dependent manner (Figures 14D-E and 15C, right
panels). In contrast, exogenous ornithine had no effect on cell growth (Figure
13

C). Stated another way, the growth advantage conferred by ARG2 loss in

kidney cells is reversed specifically by supplying exogenous polyamines. To
determine if ODC1 deficiency reverses polyamine overproduction in ARG2reconstituted 786-O cells (see Figure 14A), CRISPR/Cas9 was used to
achieve 70% deficiency in ODC1 protein in 786-O cell pools using ODC1
sgRNA-3 (Figure 14F). Soft agar colony assays revealed a significant rescue
of colony formation when ARG2 expression and ODC1 deficiency were
combined (Figure 14G). These data suggest that ARG2-dependent polyamine
production, in addition to PLP consumption, directly modulates renal epithelial
cell growth, where ccRCC cells experiencing tumor hypoxia avoid an
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overabundance of polyamines (due to uptake) by “rewiring” the biosynthetic
machinery for these metabolites.
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Figure 12. ccRCC Tumors Exhibit Increased Polyamine Levels and
Correspondingly Alter Gene Expression to Lower de novo Synthesis
A.
Schematic representation of polyamine biosynthesis. Each enzyme
contains a corresponding box plot with TCGA mRNA data in normal (N) and
ccRCC (T) samples. Each y-axis represents the normalized RNA-seq reads of
the gene; n = 69 normal kidney and 480 tumor samples. *** p< 0.001
B.
786-O cells grown under hypoxia (0.5% O2) and supplemented with
various concentrations of putrescine (Put), and HK-2 cells grown in 1 mM
glucose, 1% FBS conditions, supplemented with Put. Cell growth was
assessed by WST-1 assays, and error bars represent SEM from 10 replicate
wells. Prostate cancer (LnCaP) cells were supplemented with various
concentrations of putrescine, and cell counts performed over the indicated
times. Error bars represent SEM from 4 replicate wells.
C.
Polyamine metabolite abundance in primary ccRCC combining two
independent datasets, n = 158 (Hakimi et al., 2016; Li et al., 2014). Data are
displayed as the fold change in metabolite abundance of each tumor,
normalized to its control sample.
D.
Quantification of immunohistochemistry staining of primary ccRCC
tissue microarray, demonstrating reduced ODC protein in ccRCC tumors. *** p
<0.001, Welch’s t-test. See image in Figure 13B.
E.
Kaplan-Meier survival analysis of OAZ1 expression (from TCGA data)
in ccRCC. ‘Low’ versus ‘High’ data are segregated based on the median
expression of OAZ1. Mantel-Cox log-rank test was performed. Abbreviations:
OAZ, ornithine decarboxylase antizyme; AZIN1, ornithine decarboxylase
antizyme
inhibitor;
ODC1,
ornithine
decarboxylase1;
AMD1,
adenosylmethionine decarboxylase1; SRM, spermidine synthase, SMS,
spermine synthase.
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Figure13. ARG2 Controls Polyamine Production Which Inhibits Growth
88

A.
ARG2 expression results in marked changes in putrescine levels but does not
affect absolute ornithine or glutamate concentrations. Control or ARG2-/- HK-2 cells
were grown in 1% FBS and 1 mM glucose for 24 hours (upper panels), whereas control
or ARG2-expressing 786-O cells were grown under hypoxia (0.5% O2) for 48 hours
(lower panel), followed by quantification of total ornithine, putrescine, and glutamate
pools with LC/MS. Error bars represent SEM of 5 replicates.
B.
Steady state concentrations (pmol/ mg protein) of pyridoxal phosphate (PLP)
precursors upon pyridoxal kinase (PDXK) expression. SD values represent 5 technical
replicates.
C.
Immunohistochemistry images of primary ccRCC tissue microarrays, N = normal,
T = tumor (US Biomax); quantification of staining intensity displayed in Figure 10D.
Welch’s t-test. ***p < 0.001, a two-way ANOVA with Tukey’s multiple comparisons test
was conducted for each dataset unless otherwise specified.
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Figure 14. ARG2 Expression Controls Polyamine Concentration and
Subsequent Growth Modulation
A.
Schematic representation of 15N4-Arginine contribution to polyamine
biosynthesis. Closed red circles represent heavy nitrogen (15N) while open
black circles represent carbon atoms (12C).
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B.
ARG2 increases arginine utilization for polyamines. Top panel, HK-2
cells grown in 1% FBS and 1 mM glucose for 24 hours and then supplemented
with 15N4-Arginine for an additional 24 hours. M2 enrichment represents the
proportion of each metabolite containing two - 15N atoms (atom percent excess
[APE]). Bottom panel, 786-O cells grown under hypoxia (0.5% O2) for 48 hours
and then supplemented with 15N4-Arginine for an additional 24 hours. Error
bars represent SEM of 5 replicates.
C.
786-O cells grown under normoxia or hypoxia (0.5% O2) for 48 hours
followed by quantification of total polyamine pools with LC/MS. Error bars
represent SEM of 8 replicates.
D-E. HK-2 cells grown in 1% FBS and 1 mM glucose and supplemented with
various concentrations of putrescine or spermine. Error bars represent SEM of
8 replicates.
F. CRISPR/Cas9 mediated deletion of ornithine decarboxylase (ODC1) in
ARG2 reconstituted 786-O cells. Numbers below ODC1 western blot images
represent the quantified fold change in protein compared to 786-O lines with
vector or ARG2, respectively.
G. ODC1 loss in 786-O cells reverses ARG2-mediated growth suppression in a
soft agar colony formation assay. Error bars represent SEM of 3 replicate
wells. *p < 0.05, **p < 0.01, ***p < 0.001, a two-way ANOVA with Tukey’s
multiple comparisons test was conducted for each dataset unless otherwise
specified.
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Figure 15. ARG2 Effects on Polyamine and Amino Acid Biosynthetic Pathways
A.
Control or ARG2-/- HK-2 cells were grown in 1% FBS and 1 mM glucose for 24
hours (either normoxia or 0.5% O2) followed by quantification of total polyamine pools
with LC/MS. Error bars represent SEM of 5 replicates. All media contained 2.5 mM
putrescine in these assays.
B.

LnCaP cells cultured with indicated concentrations of putrescine.

C-D. Control or ARG2-/- HK-2 cells were grown in 1% FBS and 1mM glucose and
supplemented with various concentrations of spermidine or ornithine. Error bars
represent SEM of 8 replicates. *** p< 0.001, as indicated for Figure 12.
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Urea Cycle Enzymes ASS1 and ASL Exhibit Diminished Expression in ccRCC
tumors
We performed metabolic gene set analysis on mRNA expression data
from the cancer genome atlas (TCGA) with 538 ccRCC tumors and 72 normal
kidney samples (Li et al.). Based on these analyses, we ascertained that genes
encoding enzymes of the urea cycle are under- expressed in ccRCC tumors
when compared to the normal kidney (Figures 16A and 16B). We focused on
urea cycle enzymes argininosuccinate synthase (ASS1) and argininosuccinate
lyase (ASL) that convert citrulline and aspartate to arginine and fumarate via
argininosuccinate. Survival data from TCGA indicated that patients with high
combined expression of ASS1 and ASL (n=92) did significantly better than
patients with low combined expression of ASS1 and ASL (n=352) (Figure 16C
and Figure 17A-B). Furthermore, both ASS1 and ASL are under-expressed in
ccRCC tumors when compared to the normal kidney tissue (Figure 16D). This
is also reflected in the lowered protein abundances of ASS1 and ASL in
matched primary patient tumor-normal cores (Figure 16E and Supp Figure
17C). Finally, several ccRCC cell lines have decreased ASS1 and ASL when
compared to the immortalized renal epithelial cell line, HK-2 (Figure 16F).

93

Figure 16. ccRCC Tumors Exhibit Alterations in Urea Cycle Components
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A. Metabolic gene set analysis of mRNA-seq data from The Cancer Genome Atlas
(TCGA) classified based on KEGG. A ranked list of metabolic gene sets was
generated based on log2 scale fold expression changes in ccRCC tumors (n=538)
normal kidney (n=72).
B. The urea shunt as configured in the kidney. * = Citrulline from diet.
C. Survival analysis based on TCGA expression data for ASS1 and ASL high (n=90)
and ASS1
and ASL low (n= 236) patients. *p< 0.05
D. mRNA-seq data of ASS1 and ASL in normal kidney versus ccRCC tumors. (TCGA)
****
p< 0.001, ***p = 0.001, Mann-Whitney test.
E. Representative immunohistochemistry images with quantification for ASS1 or ASL
protein expression in matched tumor-normal pairs (Biomax KD601) n=50. Scale bars
represent 100µm.
****
p< 0.001, Welch’s t-test.
F. ASS1 and ASL protein levels in HK-2 (immortalized kidney epithelial) cells and
various ccRCC cell lines. HSP90 and Actin serve as loading controls.
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Figure 17. ASS1 and ASL expression affects survival in ccRCC patients
A. Survival curve based on ASS1 expression in patients from the TCGA. (High n=176,
low n=352)
B. Survival curve based on ASL expression in patients from the TCGA (High n=258 low
n=270)
C. Log2 scale fold change in ASS1 and ASL protein levels in tumors when compared
to normal kidney (n=108, Clark et al.)
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ASL Re-expression Alters Growth in Normal Kidney and ccRCC Cell
In order to recapitulate ASL loss in normal kidney cells we used shRNA
mediated knockdown ASL in HK-2 cells (Figures 18A and 18B) with two independent
shRNAs (SH-4, SH- 5), while a scrambled shRNA was used as control. ASL
knockdown enhanced growth in HK-2 cells in 2D culture (Figure 18C) and a 3D soft
agar colony formation assay (Figure 18D). Re- expression of ASL alone in 786-O and
UMRC2 cells modestly suppressed growth in a 3D soft agar colony forming assay
(Figure 19). Similar results were obtained for ASS1 re-expression in ccRCC (Ochocki
et al., 2018). With the aim of combined re-expression of ASS1 and ASL, we reexpressed ASL in 769-P cells that have substantial ASS1 expression (Figure 18E).
This in turn significantly suppressed growth in 2D culture (Figure 18F), where cells
were grown in low serum (1% FBS, standard DMEM) conditions. Furthermore, this
suppression was reproduced in a 3D Matrigel based spheroid assay and a soft agar
colony formation assay (Figures 18G and 18H).
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Figure 18. ASL Expression Alters Growth in Normal Kidney and ccRCC Cells
A. mRNA expression levels of ASL in HK-2 cells post knockdown with two independent
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shRNAs. Scrambled shRNA was used as a control.
B. Protein levels of ASL in HK-2 cells after shRNA knockdown. Actin is the loading
control.
C. and D. ASL knockdown enhances HK-2 cell growth in (C) 2D and (D) 3D soft agar
colony forming assay. In C, cells were grown in 1% FBS and standard DMEM. Error
bars represent SEM from three replicate wells. **p< 0.01, *p< 0.05
E. Ectopic expression of ASL in 769-P ccRCC polyclonal populations. HK-2 cells used
as physiologic control. HSP90 and Actin serve as loading controls.
F- H. ASL re-expression in 769-P cells suppresses growth in (F) 2D, (G) 3D Matrigel
spheroids, and (H) 3D soft agar colony forming assay. 769-P cells expressing empty
vector were used as a control. In F, cells were grown in 1% FBS and standard DMEM.
**
p< 0.01, *p< 0.05
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Figure 19. ASL Expression Suppresses Growth in a ccRCC cells
A. Ectopic expression of ASL in 786-O polyclonal population. Actin is used as the
loading control.
B. 3D soft agar colony forming assay with 786-O cells expressing empty vector control
and ASL cDNA. **p< 0.01
C. Ectopic expression of ASL in UMRC2 polyclonal population. Actin is used as the
loading control.
D. 3D soft agar colony forming assay with UMRC2 cells expressing empty vector
control and ASL cDNA. **p< 0.01
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Combined Re-expression of ASS1 and ASL Suppresses Growth and Alters
Aspartate Metabolism in ccRCC Cells
769-P have a number of limitations, chief among them is their inability to form
in vivo xenograft tumors. In order to explore ASS1 and ASL mediated growth
suppression in an in vivo setting, we re-expressed ASS1 and ASL in 786-O cells
(Figure 20A). This re-expression suppresses growth in a 2D growth assay (1% FBS,
DMEM) (Figure 20B), and a soft agar colony forming assay (Figure 20C). To further
elucidate the effects of combined re-expression of ASS1 and ASL in 786-O cells, we
measured steady-state levels of intracellular amino acids (Figure 20D). The combined
re-expression alters amino acid levels, specifically it depletes cellular aspartate and
glutamine levels. Aspartate is vital to cellular growth and lowered aspartate levels can
have detrimental effects on cell growth, affecting pyrimidine production among other
things. (Sullivan et al., 2015, Birsoy et al., 2015 Rabinovich et al., 2015). The cells try
to make up for the deficit in intracellular aspartate by making more aspartate from
glucose and glutamine (Figure 20E and F). This puts an additional metabolic burden
on the cells and slows down proliferation, specifically DNA production as evidenced by
an Edu incorporation assay (Figure 20G). ASL re-expression in 769-P cells also
showed similar trends in intracellular aspartate and glutamine levels (Figure 21A).
Additionally, 769-P cells expressing ASL exhibit a peculiar sub-G0 peak (Figure 21B)
in cell cycle experiments hinting at a glitch in pyrimidine synthesis and DNA replication.
Furthermore, addition of exogenous pyrimidines to the culture medium rescues growth
in 769-P cells (Figure 21C).
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Figure 20. Combined Expression of ASS1 and ASL in ccRCC cells Suppresses
Growth and Alters the Metabolic Landscape
A. Combined ectopic expression of ASS1 and ASL in 786-O polyclonal population.
HSP90 serves as the loading control, while HK-2 cells and the normal kidney are
normal controls.
B. ASS1+ ASL expression suppresses growth in 786-O cells in a 2D growth assay.
Error bars represent SEM of 7 wells, cells were grown in 1% FBS in complete DMEM.
***
p< 0.001
C. 3D soft agar colony forming assay with 786-O cells expressing empty vector control
and ASS1+ ASL cDNA. Error bars represent SEM of 3 wells. *p< 0.05
D. Steady-state amino acid in 786-O cells expressing empty vector and ASS1+ASL
cDNA. Error bars represent SEM of 3 technical replicates. **p< 0.01
E. Schematic representation of 15N2-Glutamine labeling into aspartate, orotate, and
argininosuccinate. Argininosuccinate synthase (ASS1), Carbamoyl-phosphate
synthetase 2, aspartate transcarbamylase and dihydroorotase (CAD enzyme
complex). The filled in squares represent heavy nitrogen (15N) while clear circles
represent carbon atoms (12C).
13
F. Schematic representation of C6-Glucose labeling into aspartate. The filled in circles
represent heavy carbon atoms (13C).
G. EdU incorporation assay with 786-O cells expressing empty vector and ASS1+ASL
cDNA. Error bars represent SEM of 3 technical replicates. *p< 0.05
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Figure 21. ASL Expression in 769-P cells Alters Amino Acid Pools and Affects
DNA Replication
A. Steady-state amino acid in 769-P cells expressing empty vector and ASL cDNA.
Error bars represent SEM of 3 technical replicates. ****p< 0.001, ***p< 0.001
B. Representative images of cell cycle analyses of 769-P cells indicating a sub-G0
peak in cells expressing ASL cells at 0 hours and 24 hours.
C. Exogenously provided pyrimidines (cytidine + thymidine) partially rescue growth in
769-P cells expressing ASL. Error bars represent SEM of 7 wells. *p< 0.05, ***p< 0.001.
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Combined Re-expression of ASS1 and ASL Suppresses ccRCC Growth in vivo
There is a strong selective pressure against ccRCC cells with combined reexpression of ASS1 and ASL and maintaining physiological levels of expression has
not been trivial (data not shown). To overcome this, we resorted to a doxycycline
inducible system of expression (Figure 22A). Sustained, combined re-expression of
ASS1 and ASL, under doxycycline control, significantly suppressed growth in a
subcutaneous xenograft model, where the mice were fed chow with doxycycline
(200mg/kg) (Figure 22B). These xenografts exhibit lowered but not significant
phosphorylated histone H3 (pH3) levels (Figure 22C), significantly enhanced cleaved
caspase

3

(CC3)

(Figure

22D)

and

p21

staining

(Figure

22E).

These

immunohistochemical analyses point to slower proliferation, increased apoptosis and
defects in cell cycle. It is conceivable that aspartate availability is further limited in a
harsher in vivo setting, augmenting the growth suppression observed in vitro.
Interestingly, 786-O cells with ASL re-expression alone (Figure 19A), exhibit modest
growth suppression in vivo (Figure 23A). Although, this suppression is limited to tumor
volumes. Moreover, immunohistochemical analyses for pH3, CC3, and p21 were not
significantly different (Figure 23B-D). 786-O xenograft tumors with just ASL reexpression, however, have significantly decreased levels of CD31(Figure 23E), a
protein staining blood vessels, indicating changes in tumor vasculature. We assessed
levels of various angiogenic proteins in these tumors using a membrane-based
sandwich immunoassay (Figure 23F). ASL re- expression in 786-O xenograft tumors
broadly alters levels of angiogenic proteins. The exact mechanism of these changes in
unknown but can be associated with nitric oxide synthesis and catalytic activity
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independent roles of ASL.
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Figure 22. Combined Re-expression of ASS1 and ASL suppresses growth in vivo
A. Combined doxycycline induced ectopic expression of ASS1+ ASL in 786-O cells.
HSP90 is used as a loading control.
B. 786-O subcutaneous xenograft tumor growth in nude mice, where cells have
doxycycline induced expression of ASS1 and ASL or empty vector. (n = 6)
C. Immunohistochemistry staining and quantification for phosphorylated histone H3 as
marker for proliferation in xenograft tumors. Scale bars are at 100µm.
D. Immunohistochemistry staining and quantification for cleaved caspase 3 as marker
for apoptosis in xenograft tumors. Scale bars are at 100µm. **p< 0.01.
E. Immunohistochemistry staining and quantification for p21 as marker for
proliferation in xenograft tumors. Scale bars are at 100µm. ***p< 0.001.
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Figure 23. Re-expression of ASL Alone in 786-O Cells Does Not Suppress Growth
in vivo
A. 786-O subcutaneous xenograft tumor growth in nude mice, where cells expression
ASL or empty vector. (n = 5)
B. Immunohistochemistry staining and quantification for phosphorylated histone H3 as
marker for proliferation in xenograft tumors. Scale bars are at 100µm.
C. Immunohistochemistry staining and quantification for cleaved caspase 3 as marker
for apoptosis in xenograft tumors. Scale bars are at 100µm.
D. Immunohistochemistry staining and quantification for p21 as marker for
proliferation in xenograft tumors. Scale bars are at 100µm.
E. Immunohistochemistry staining and quantification for CD31 as marker for
vasculature in xenograft tumors. Scale bars are at 100µm. *p< 0.05.
F. Heat map showing the levels of various angiogenic proteins in 786-O xenograft
tumors expressing ASL or empty vector.

109

DISCUSSION
Nearly 40% of ccRCC patients exhibit ARG2 copy number loss, likely reflecting
ARG2’s position at the nexus of dual mechanisms of tumor inhibition in ccRCC: 1)
depleting available PLP pools, thereby removing a critical cofactor for multiple essential
enzymatic reactions, and 2) increasing polyamines to toxic levels. It is now clear that
altered metabolism plays an important role in cancers of the kidney, an organ
responsible for excreting excess ammonia (as urea), maintaining inorganic ion
homeostasis, and generating hormones (e.g. erythropoietin) and glucose. Of note, while
ASS1 resides on chromosome 9 (9q34.11), ARG2 is located on 14q (14q24.1), a
chromosome frequently deleted in ccRCC (Shen et al., 2011). Shen et al. previously
proposed that multiple kidney cancer tumor suppressor genes exist on 14q (in addition
to HIF1A), and ARG2 represents a very likely candidate. Only 3 out of 448 (0.7%) cases
reported in the TCGA exhibit a deep deletion at the locus, whereas the remaining 38%
cases with copy number variation exhibit mono-allelic copy number loss. As ARG2
mRNA levels are significantly decreased and ARG2 protein expression essentially
undetectable, we conclude that any retained ARG2 alleles must be silenced in ccRCC
tumors and cell lines. Interestingly, ASL exhibits copy number gain in ccRCC. We
attribute this to its location on chromosome 7q (7q11.21), close to a pericentromeric
region. Regions adjoining the centromere are often duplicated, which may explain the
higher copy number of ASL detected in ~40% ccRCC.
Although gluconeogenesis and glycogen storage represent the most significantly
down-regulated metabolic pathway in ccRCC, the urea cycle enzymes display a similar
degree of repression in these tumors. We sought to determine if suppression of the urea
cycle contributes directly to ccRCC disease progression. Whereas multiple cancers
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exhibit decreased ASS1 and ASL protein abundance (Huang et al., 2013; Kobayashi et
al., 2010; Rabinovich et al., 2015), ccRCC appear to have suppressed additional urea
cycle enzymes, including ARG2. Re-expressing ASS1 (Figure 6) or ASL (Figure 18) in
ccRCC cells inhibited proliferation, although our data indicate that ARG2 has more
potent tumor suppressive effects in this setting.

Nevertheless, which urea cycle

intermediates are critical for these effects remains somewhat open-ended. ASS1deficient sarcoma cells depend on aspartate diverted away from the urea cycle to
support de novo nucleotide production and DNA replication (Rabinovich et al., 2015).
We observed similar recuse with nucleosides in ASS1+ASL re-expressing cells (Figure
23), but not in ARG2 re-expressing cells, perhaps hinting at distinct mechanisms of
suppression. It is also important to contrast our results with those presented in the recent
report by Kim et al., where Kras/LKB1mutant lung cancers overexpress the urea cycle
enzyme carbamoyl phosphate-1 to maintain pyrimidine levels and DNA synthesis (Kim
et al., 2017). ccRCC instead repress the expression of multiple urea cycle enzymes to
also maintain nucleotide pools by different means, i.e. conservation of a critical
biosynthetic cofactor (PLP) that ultimately supports their generation. ARG2-expressing
ccRCC xenografts also exhibited decreased mTORC1 activity, coincident with
decreased pools of arginine, aspartate, and glycine, suggesting that disrupted amino
acid homeostasis might result in reduced mTORC1 signaling and cell growth. However,
high levels of mTORC1 activity conferred by constitutive mTORC1 and RagB activity
also failed to reverse ARG2-mediated growth suppression.
ARG2 expression had significant effects on pyridoxine metabolism, in that its
deletion in renal epithelial cells, or reconstitution in ccRCC cells, changed overall
intracellular PLP levels by a surprising 25-35%. Given the significant role of this
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essential vitamin B6 component in numerous metabolic reactions critical for amino acid
synthesis, nitrogen homeostasis, and glycogen production, ARG2 loss in ccRCC
appears to maintain sufficient PLP to support more than 140 biosynthetic reactions that
contribute to increased biomass and cell division. In fact, changes in PLP pools likely
account for the substantial disruption of amino acid and subsequent nucleotide
abundance (due to changes in aspartate levels) observed in ARG2 expressing
xenografts. In aggregate, pyridoxine metabolism represents an understudied pathway for
future therapeutic strategies for ccRCC treatment, with pyridoxal kinase a highly
appealing potential drug target.
Metabolic tracing experiments with

15

N4-arginine revealed that ARG2 expression

plays a critical role in arginine conversion to putrescine and urea. Our data indicate that
human ccRCC tumors accumulate high levels of polyamines, despite having reduced
ARG2 expression, suggesting that these cells import exogenous polyamines from the
circulation or tumor microenvironment. The growth advantage conferred to normal renal
epithelial cells by ARG2 deficiency is reversed by exogenous polyamines, suggesting
that one benefit of ARG2 deficiency in ccRCC cells is avoiding toxic polyamine
concentrations by reducing de novo synthesis of putrescine and spermidine. Relatively
little is known about how polyamines regulate cancer cell behavior, particularly in
ccRCC, although polyamine biosynthetic enzymes are controlled at the level of
transcription, translation, and protein degradation by a variety of highly conserved
feedback loops (see Figure 12A). While intracellular polyamines can support cell division
and anabolic metabolism (Babal et al., 2002; Svensson et al., 2008; Tsujinaka et al.,
2011), they can also be converted to toxic byproducts like acrolein (Moghe et al., 2015;
Stevens and Maier, 2008). Preliminary experiments indicate that ARG2-reconstituted
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ccRCC cells accumulate higher levels of acrolein than control cells (data not shown),
providing an explanation for why polyamine overabundance results in decreased cell
vitality. Therefore, further investigation of polyamine influences on renal cancer
progression is highly warranted.
While metabolic adaptations supporting tumor cell growth and division have been
extensively studied (Palm and Thompson, 2017; Vander Heiden and DeBerardinis,
2017), global metabolic shifts contributing to tumor cell survival remain less clear
(Kamphorst et al., 2013; Young et al., 2013). Our findings demonstrate how a single
metabolic pathway significantly contributes to both processes: PLP conservation
promotes biomass expansion, while suppression of polyamine synthesis enhances cell
survival when tumor hypoxia increases polyamine uptake. A third essential process
underlying disease progression is evasion of the immune system. The overall goal of
our studies is to identify consistent (if not universal) metabolic differences between
healthy kidney tissue and ccRCC, a genetically diverse cancer exhibiting significant
intratumoral genomic heterogeneity. Cancer metabolism research has focused primarily
on central carbon, amino acid, and lipid pathways, and ccRCC has been previously
characterized as a metabolic disease with consistent changes in glycolysis,
gluconeogenesis, and lipid storage. We show here that ammonia metabolism can also
be of central importance to ccRCC disease progression.
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CHAPTER 4: CONCLUSIONS
Advances in engineering and computational modeling, along with sophisticated
clinical processes, have ushered in a renaissance for the field of cancer metabolism. We
now have an enhanced understanding of complex metabolic phenomena and hope to
utilize this knowledge in the development of better therapies for cancers. Altered
metabolism is a key feature of not just malignancies but also a number of in-born errors
of metabolism (IEM). Chapter 1 expounds on the common metabolic themes between
IEM and transformed cells. Chapter 1 further introduces clear cell renal cell carcinoma
(ccRCC) as a model for studying metabolic rewiring. I focus on the role of urea cycle
enzymes argininosuccinate synthase 1 (ASS1), argininosuccinate lyase (ASL), and
arginase 2 (ARG2) in ccRCC progression. The urea cycle is downregulated in ccRCC
tumors when compared to the normal kidney, and I hypothesize that urea cycle enzymes
act as potential metabolic tumor suppressors in ccRCC.
In Chapter 3, I demonstrate that urea cycle enzymes and intermediates have
lowered abundances in ccRCC tumors when compared to the normal kidney.
Furthermore, loss of these enzymes enhances proliferation in normal kidney cells, while
their re-expression suppresses growth in ccRCC cells.
ARG2 is a mitochondrial enzyme that is lost in ccRCC tumors. Loss of ARG2
promotes tumorigenesis in two important ways – preserving intracellular pools of
pyridoxal phosphate and preventing a toxic build-up of polyamines (Figures 12-14).
Thus, ARG2 is a key regulator of cellular growth in ccRCC tumors, and its loss alters
arginine metabolism while promoting malignant transformation.
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In addition to ARG2, ccRCC tumors also downregulate two additional urea cycle
enzymes ASS1 and ASL. These enzymes are spatially distinct from ARG2, as they
reside in the cytosol. ASS1 and ASL lie at a critical metabolic hub in the cell. Reactions
catalyzed by these enzymes are involved in aspartate catabolism, and arginine and nitric
oxide biosynthesis. Loss of ASS1 and ASL helps cells redirect aspartate towards
pyrimidine synthesis (Figure 22) and support enhanced proliferation. Although the role of
aspartate conservation and ASS1 and ASL loss have been discussed extensively
elsewhere, my work elucidates their importance in ccRCC. Furthermore, my research
indicates that though ASL expression alone does not suppress growth in ccRCC cells, it
impacts tumor vasculature, perhaps through its role in nitric oxide synthesis.
Overall, my work adds to our understanding of urea cycle enzymes in a context
independent of ureagenesis, their role in ccRCC progression, and uncovers novel
potential metabolic vulnerabilities in ccRCC.
Future Directions
Exploring non-enzymatic contributions of ASS1 and ASL in ccRCC progression
My work demonstrates that ARG2 mediated suppression in ccRCC depends on
its catalytic activity (Figure 6). However, the same has not been explored for ASS1 and
ASL. Erez et al., have determined a structural role for ASS1 and ASL in nitric oxide (NO)
synthesis. ASS1 and ASL form a tripartite complex with nitric oxide synthase (NOS) and
shuttle the arginine produced by ASL towards NO generation. With this background we
have generated point mutations in ASS1 and ASL that render them catalytically inactive.
The goal is to re-express the catalytically dead versions of these enzymes in ccRCC
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cells and evaluate the effect on growth. Furthermore, it will be intriguing to assess the
tripartite complex formation in kidney cells and the effect of malignant transformation in
ccRCC (Erez et al., 2011).

Investigating the role of ASS1 and ASL in Nitric Oxide Synthesis
As the reactions catalyzed by ASS1 and ASL are also a part of the citrulline-NO
cycle, it would be important to investigate the effect of their loss on NO synthesis.
Jansson et al., reported lowered NOS activity in ccRCC tumors. Our preliminary studies
validate these results (data not shown). It will be interesting to further explore the effects
of NOS downregulation in ccRCC. NO is a potent regulator of vascular tone and ccRCC
tumors are highly vascular. It will be critical to establish a role for lowered NO signaling
in ccRCC tumors with VHL loss and HIF activation. (Jansson et al., 1998).
Evaluating the role of the urea cycle in ccRCC tumor immune microenvironment
Urea cycle loss naturally makes ccRCC cells arginine auxotrophs (Figure 5). As
tumor infiltrating T cells clearly rely on arginine for their cytotoxic activity (Geiger et al.,
2016), ccRCC cells’ dependency on circulating arginine suggests that this metabolic
adaptation contributes to immunosuppression in the tumor microenvironment.
Competition for microenvironmental arginine and serine, (Ma et al., 2017), provides an
explanation for the success of immune checkpoint blockade in only a subset of ccRCC
patients (Hammers, 2016; Joseph et al., 2017). If ccRCC tumor cells deprive infiltrating
lymphocytes (and other immune cells) of critical exogenous metabolites due to urea
cycle deficiency, overcoming the effects of PD-1/PD-L1 activity would fail to fully restore
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anti-tumor immunity. Our findings also raise the intriguing possibility that immunotherapy
approaches could be improved by dietary means (i.e. arginine supplementation) for
individuals afflicted with renal cancer.
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